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Over the past three decades, high-throughput screening has resulted in a discovery 
pipeline consisting mostly of highly potent but lipophilic compounds exhibiting poor 
aqueous solubility and classified as Biopharmaceutics Classification System (BCS) Class 
II. Since poor solubility limits absorption and bioavailability, efforts have been made to 
develop supersaturating delivery systems such as amorphous solid dispersions (ASD) that 
enhance the apparent solubility of the drug without sacrificing its thermodynamic activity. 
The performance of these dispersions is often tested in ‘closed’, non-sink compendial 
dissolution testing apparatus that lacks an absorptive sink. The supersaturated solution 
generated upon ASD dissolution is metastable with respect to the stable crystalline phase 
and can undergo amorphous and/or crystalline precipitation. The rate of precipitation 
depends upon the degree of supersaturation.  
In the absence of absorption, during non-sink dissolution testing, high supersaturation 
can drive more precipitation than that which occurs in vivo where continuous drug 
absorption from the intestinal lumen decreases drug concentration, which in turn decreases 
the driving force for precipitation. Unsurprisingly, many in vitro studies with non-sink 
dissolution testing have failed to predict the in vivo performance of formulations of BCS-
II drugs, which by definition, have high intestinal permeability. A simultaneous dissolution 
and absorption testing apparatus called the side-by-side diffusion cell allows drug to diffuse 
from the donor to a receiver compartment across a membrane that separates the two. 
However, small surface area of the membrane results in very low rates of drug absorption 
and very long, unphysiological experimental time scales.  
The first goal of this study was to develop and validate an artificial gut simulator 
apparatus (AGS) consisting of a hollow fiber-based absorption module suspended in the 
drug donor. The hollow fibers provide a large surface area for absorption, significantly 
improving mass transfer rate of drugs from the donor into the aqueous receiver media in 
the hollow fiber lumen. Continuous pumping of the drug-free receiver media into the lumen 
helps maintain an absorptive sink. A theory for mass transfer across the hollow fiber 




absorption was attained by tuning the AGS operating parameters per the theoretical model. 
This is an important step in developing a biorelevant test for BCS-II drugs.  
The next goal of this project was to understand how absorption impacts dissolution of 
ASDs and subsequent crystallization from supersaturated solutions of a model BCS-II 
compound, ketoconazole. Relative to a non-sink ‘control’, continuous drug removal by 
absorption enhanced ASD dissolution and significantly decreased both amorphous and 
crystalline precipitation. This can be attributed to both a decreased driving force for 
precipitation due to lower drug concentration in the AGS donor as well as to redissolution 
of any precipitate that is formed to replenish the drug in solution lost to absorption. On the 
other hand, polymer excipient added to the ASD to stabilize the drug against crystallization 
during storage and dissolution reduced the drug’s absorption rate by possibly interacting 
favorably with the free drug species and reducing the drug’s thermodynamic activity. 
Simple analytical techniques used in conjunction with the AGS helped decouple and 
understand the impact of dissolution, precipitation and speciation on absorption and vice-
a-versa.  
The final goal of this project was to implement a scheme to establish in vitro/in vivo 
correlation with another BCS-II drug, dipyridamole, by inputting the drug concentration 
absorbed by the AGS receiver media into a compartment-based disposition model to 
ultimately predict the in vivo plasma concentration-time profile of the drug. The human 
intestinal absorption rate constant of dipyridamole, determined from Caco-2 cell 
monolayer permeability coefficient, was used to tune the AGS. Gastric emptying was 
simulated at a physiological rate to ensure a physiological rate of supersaturation 
generation as the weakly basic dipyridamole is solubilized and emptied from acidic gastric 
compartment into a neutral duodenum. This methodology of simulating gastric emptying 
and absorption enabled accurate prediction of drug in vivo intestinal and plasma 
concentration-time profiles. This approach and apparatus is anticipated to be of great utility 
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1.1.1 Physical chemistry of supersaturated solutions 
Oral drug administration, to date, remains the most preferred and common route of drug 
delivery. Following oral administration, the drug first dissolves in the gastrointestinal (GI) 
media and then permeates across the GI membrane to enter systemic circulation. Per 
Lipinski’s ‘Rule of Five’, proposed more than two decades ago, the desirable 
physicochemical properties for efficient oral delivery include high aqueous solubility and 
high phospholipid membrane permeability.1 
However, in the last three decades, powerful computational chemistry and high-
throughput screening technologies employed in the drug discovery phase have resulted in 
a pipeline consisting mostly of highly potent but lipophilic, large molecular weight 
compounds that exhibit poor aqueous solubility.1–4 The Biopharmaceutics Classification 
System (BCS) categorizes drugs into four classes based on their solubility and 
permeability. BCS-II drugs include those with low aqueous solubility and high intestinal 
membrane permeability, and now constitute 40% of the marketed drugs and 90% of new 
drug candidates.5  
 To improve oral bioavailability, several formulation strategies have been adopted that 
have a theoretical basis in the Noyes-Whitney equation coupled with the Nernst-Brunner 










 Eq. (1.1) states that the rate of drug dissolution from a tablet particle is a function of 
the surface area A that is available for dissolution, the concentration gradient between the 
tablet surface (drug solubility, 𝐶𝑠) and bulk of the solution (𝐶) as well as boundary layer 
thickness h and diffusion coefficient D. Now D and h are somewhat beyond the control of 
the formulation scientist. They depend on the media that is available in the gut and the 
existing hydrodynamics. As a result, many solubility enhancing formulation strategies to 
improve 𝐶𝑠 have emerged. The most common approaches used in the marketed products 
include incorporation of cosolvents, surfactants and cyclodextrins and formulation of salts, 
polymorphs, cocrystals, lipid-based systems, and amorphous solids.7 These strategies 
result in an enhanced solution concentration either by increasing the drug’s equilibrium 
solubility or by generating supersaturated solutions. 
The fundamental difference between a solubilized solution and a supersaturated 
solution is the thermodynamic activity of the drug in solution; in a supersaturated solution, 
by definition, it exceeds the thermodynamic activity of the crystalline drug, while in a 
solubilized solution, the thermodynamic activity of the drug remains at or below that of the 
crystalline form.6 Thermodynamic activity refers to the free or unbound fraction of the drug 
in solution. The other species include drug molecules bound to solubilizing excipients such 
as cyclodextrin complexes, surfactants micelles and cosolvents.  
It is now widely recognized that only the free drug molecules provide the driving force 
for absorption and that solubilization by micelles and complexes can lead to a reduction in 
the absorption rate.8,9 For instance, Miller et al. demonstrated that with an increase in 
sodium lauryl sulfate and sodium taurocholate concentration beyond the critical micelle 




perfusion assay was observed.10 This lack of correlation between solubility and 
permeability is known as the “solubility-permeability” interplay wherein the increased 
apparent solubility of a drug is alone insufficient to result in an increase in oral 
bioavailability.10–14  
Formulation strategies like amorphization of the crystalline drug to generate high free 
energy state and disordered lattice structures, on the other hand, can lead to a remarkable 
enhancement of dissolution rate and dissolved drug concentrations. The supersaturated 
solutions result in an increased fraction of free drug available, or in other words, enhanced 
thermodynamic driving force, for absorption.6 The concentration of the dissolved drug, 
however, cannot exceed a critical miscibility concentration or the amorphous solubility of 
the drug in a given aqueous media.6  
Amorphous solubility is the concentration of drug attained in solution following 
equilibration between the solution phase and amorphous material.6 Strictly speaking, such 
an equilibrium is impossible since the crystalline material is the thermodynamically stable 
form and the high free energy amorphous polymorph or the metastable supersaturated 
solution will crystallize into the next stable polymorph as per Ostwald’s rule of stages.15–
17 However, if crystallization is slow, then a metastable equilibrium can exist between the 
amorphous material and crystalline solid, which enables determination of amorphous 
solubility.6 The amorphous solubility advantage has resulted in the commercial success of 
many drugs. For example, amorphous glibemclamide displayed 14 times higher solubility 
than its crystalline form in an aqueous buffer.18 Likewise, amorphous pranlukast had 
enhanced its solubility by approximately 5.8 times in water and 19.4 times in phosphate 




However, the inherent instability of the amorphous form caused by high free energy 
remains a major barrier to its widespread adoption as a formulation strategy. Amorphous 
solids are typically stabilized by formulating homogeneous dispersions with polymers. 
Such formulations are known as amorphous solid dispersions (ASDs).20 Polymers increase 
the stability of the solid amorphous form during manufacturing and storage as well as of 
supersaturated solutions upon ASD dissolution by various mechanisms, such as forming a 
physical barrier to prevent aggregation of drug molecules, decreasing the configurational 
entropy, decreasing the drug’s thermodynamic activity through favorable drug-polymer 
interactions, and decreasing the drug’s molecular mobility by increasing the formulation’s 
glass transition temperature (Tg).
21 Nontoxic polymers including polyvinylpyrrolidone 
(PVP), hypromellose (HPMC), polyvinylpyrrolidone/vinyl acetate (PVP/VA), and 
hypromellose acetate succinate (HPMCAS) have been approved to use as excipients by the 
United States Food and Drug Administration (FDA) for oral dosage forms and have been 
adopted to manufacture several commercial ASDs.21 In spite of the stabilizing polymer, 
upon ASD dissolution, the metastable supersaturated solution generated in the GI media is 
susceptible to precipitation, the rate and type of which depends upon the degree of 
supersaturation. 
Amorphous precipitation or liquid-liquid phase separation (LLPS) refers to the 
separation of a metastable, drug-rich amorphous phase when the concentration of drug 
added to the media exceeds its amorphous solubility.6 The separated phase is mostly in the 
liquid state since the amorphous phase in contact with the aqueous phase absorbs moisture 




drug molecules whose separated amorphous phase does not exhibit a reduction in Tg, in 
which case the precipitation phenomenon is called glass-liquid phase separation22).  
It has been previously observed that the solute chemical potential or thermodynamic 
activity, 𝑎𝑎𝑞, and therefore, the flux, 𝐽, across a membrane increases linearly with an 
increase in supersaturated solution concentration up till the onset of LLPS or amorphous 







𝐶 < 𝑆 (1.3) 
𝑎𝑎𝑞 = 𝛾𝑎𝑞𝐶 
𝐶 ≥ 𝑆 (1.4) 
𝑎𝑎𝑞 = 𝛾𝑎𝑞𝑆 
where 𝐶 is the apparent drug concentration and 𝛾𝑎𝑞 is the activity coefficient of the drug in 
the aqueous media. The drug flux also depends on the drug diffusion coefficient, 𝐷, 
membrane surface area, 𝐴, and thickness, ℎ, for absorption and activity coefficient of the 
drug in the membrane 𝛾𝑚.  
Further increase in concentration does not lead to an increase in flux due to amorphous 
precipitation. Instead, a constant flux is observed.23 However, the separated amorphous 
phase, due to its high free energy and large surface area in contact with the aqueous media, 
is in dynamic equilibrium with the free drug, serving as a reservoir and rapidly redissolving 




Separation of the liquid into two phases results in a less energetic system than the initial 
homogeneous highly supersaturated system but still does not afford the lowest energy state 
which is a stable crystal in equilibrium with the saturated solution.6 The transient, 
metastable drug-rich phases would eventually transform into thermodynamically stable 
crystals.6 Several possible transformation pathways are schematically summarized in 
Figure 1.1.5 This, however, still does not present a complete picture. The drug-rich phases 
may grow, coalesce, or aggregate to further reduce the free energy of the system.5 For 
example, the diameter of drug-rich phases in the supersaturated danazol aqueous solution 
was shown to increase with time when monitored using dynamic light scattering (DLS).26 
Similarly, Ricante et al. showed that the metastable amorphous nanodroplets present in a 
supersaturated phenytoin-HPMCAS aqueous solution aggregated into irregularly shaped 
droplets prior to the formation of crystals, as measured by cryo-TEM and SAXS.27 
Although the growth, coalescence or aggregation of metastable phases is favored over the 
formation of crystalline nuclei due to the smaller free energy barrier (Ostwald’s rule of 
stages), nucleation will still occur, most likely within the drug-rich phases where a higher 
supersaturation with respect to the crystalline solubility is present, which will in turn trigger 
its transformation into thermodynamically stable crystalline phases.5 For example, the 
transformation of metastable amorphous probucol nanoparticles into crystalline ones was 
indicated by a gradual increase in the particle stiffness measured by atomic force 
microscopy (AFM).28 Similarly, crystallization within transient drug-rich nanodroplets was 
revealed in the nifedipine-HPMCAS supersaturated solution using NMR.29,30 Upon onset 
of crystallization, the concentration of the drug decreased in the solution, whereas the 




polymer was distributed in the drug-rich phase, which might assist the formation of such 











Figure 1.1. Schematic illustration of the possible nucleation pathways (classical or non-
classical) of drug in a solution.5 
 
Transformation of the metastable drug-rich phases into crystals is a 
thermodynamically inevitable process, but the kinetics of this process can be significantly 
altered by the presence of certain excipients such as polymers, so that precipitation from 
supersaturated solutions may not be observed within a reasonable experimental timescale. 
For example, Ueda et al. suggested that an increase in steric and electrostatic repulsion 
between amorphous nanodroplets caused by surface adsorption of certain polymers can 
significantly reduce the rate of nanodroplet aggregation and growth.31 The suppressing 
effects can be varied by the choice of excipient materials, as demonstrated with the PVP, 
HPMC and its derivative HPMCAS in the danazol-rich nanodroplet system. Moreover, 




subsequent growth within the drug-rich phases. Jha et al. investigated the drug and 
excipient performance in aqueous solutions using all-atom molecular dynamics 
simulations, where the effect of excipients on the mobility of drugs can be screened.32 They 
found that the aggregation and diffusivity of phenytoin can be reduced by as much as five 
orders of magnitude by the presence of HPMC and HPMCAS, indicating a significant role 
of excipient in reducing the transformation kinetics of metastable drug-rich phases during 
the dissolution of ASD. 
 
1.1.2 In vivo dissolution and absorption of insoluble drugs from ASDs 
When solid dosage forms are administered orally, the drug needs to dissolve in the human 
gastrointestinal fluids before the drug molecules can be absorbed into the systemic 
circulation and subsequently be transported to the site(s) of action. The human 
gastrointestinal fluid, however, is a complex milieu consisting of water, micelle-forming 
surfactants such as bile acids and lecithin and lipids.6 The media is buffered and highly 
dynamic. For example, the amount of bile acid and lipid secretion varies depending on food 
intake. In addition the media may contain food components as well as excipients released 
from pharmaceutical dosage forms.6 The highly complex and dynamic human GIT presents 
significant difficulties in understanding the dissolution and subsequent in vivo performance 
of pharmaceutical oral dosage forms.6 Conceptually, however, we can simplify the system 
to aid understanding. As shown in Figure 1.2, we can view the human GIT as a collection 
of interconnected “compartments”.6 The central compartment is the aqueous compartment 
into which drug dissolves and from which passive absorption of only unionized, unbound 




exist between ionized and unionized drug depending on the pKa of the molecule and the 
microenvironment pH. Peripheral to the central aqueous compartment, there are many 
other compartments or microenvironments that the bound drug can reside in. The drug in 
the peripheral compartments is not directly available for absorption. However, these 
compartments can act as reservoirs whereby drug will dissociate from these compartments 
into the central compartment to replenish the free drug that is lost to absorption. If 
dissolution from the dosage forms leads to supersaturated aqueous solutions, the drug can 
crystallize or undergo LLPS and that can eventually also redissolve to replenish drug in 












Figure 1.2. Schematic representation of ASD dissolution, gastrointestinal exchange 






1.1.3 In vitro Dissolution Testing of ASDs 
For oral solid dosage forms, the dissolution profile is an important in vitro characteristic of 
a formulation under development. Compendial dissolution testing, defined by the United 
States Pharmacopeia (USP), is widely used to obtain information during drug product 
development process such as selection of appropriate excipients or a suitable solid form of 
the compound for the desired dissolution profile.34 USP I (basket), II (paddle) and III 
(reciprocating cylinder) apparati, most commonly used for dissolution testing, had been 
primarily developed for routine quality control and batch release with little consideration 
to biorelevance.35 However, with the FDA’s specification to minimize bioavailability 
testing in humans, clinical scientists place increasing reliance on biorelevant in vitro 
dissolution testing in combination with mathematical modeling to predict in vivo 
performance.36 Physiological conditions such as fluid volume, media composition, 
hydrodynamics and transit time can have significant influence on the rate of dissolution 
and concentration of drug available for absorption. Significant efforts have been made 
towards understanding and mimicking in vivo hydrodynamics in the dissolution vessels 
and developing buffer media whose pH, buffer capacity, ionic strength, and bile acid 
composition mimic those of the in vivo gastric and intestinal fluids.37–39 However, the USP 
apparati are still closed with respect to the released drug, and any effects of drug absorption, 
which will tend to lower drug concentration in the intestinal fluid and possibly reduce the 
rate of precipitation, are suppressed.40 In this sense, the standard dissolution test may be 
more stringent than necessary, underestimating efficacy, especially for BCS-II drugs 
which, by definition, have good intestinal permeability properties. The USP Apparatus 4 




intestinal lumen.41 The USP Apparatus 4 establishes sink conditions by maintaining a 
continuous flow of drug-free dissolution medium to replace the drug-laden medium when 
operated in an open-loop mode. However, the volumes employed are usually 
unphysiologically large.42 Moreover, manual sampling (e.g. using microfilters) and 
analytical techniques (e.g. UV spectroscopy, HPLC) used with all the above compendial 
tests usually do not distinguish between free drug and nano-sized drug aggregates or drug 
that is complexed to the excipient polymers.43 While free drug is available for intestinal 
absorption, nano-aggregated or complexed drug probably is not.14 The analytical technique 
may significantly overestimate the ability of an SSDF to provide drug in a supersaturated, 
highly bioavailable form.  
 
1.2 Simultaneous Dissolution and Absorption Testing 
1.2.1 State-of-art technology 
To perform simultaneous dissolution-absorption measurements, a two-compartment 
system separated by a membrane barrier can be used wherein drug present in the donor 
compartment diffuses across the membrane into a receiver compartment. Several studies 
have been performed to develop an in vitro methodology using dissolution-absorption 
systems and to correlate the results with in vivo performance. Ginski and Polli were among 
the first to develop a dissolution/Caco-2 system to evaluate fast and slow dissolving 
immediate release formulations and correlated the performance with the clinical data.44 
Since then several modifications have been made to the membrane, fluid composition and 
configuration of the apparatus. Kataoka et al. carried out simultaneous dissolution and 




2 monolayer mounted in between, to predict oral absorption.45–48 They identified the rate-
limiting step in oral absorption and distinguished formulations based on whether the 
absorption was dissolution rate-, solubility- or membrane permeability-limited. Motz et al. 
demonstrated use of a flow-through diffusion cell to study permeation of drug dissolved 
from tablets across a Caco-2 monolayer.49 However, these cell based assays often suffer 
from high inter- and intra-lab variability, time consuming and expensive preparation steps, 
relative incompatibility with certain pharmaceutical excipients, and lower absorption 
surface area compared with the intestinal membrane.50,51 Moreover, considering that 80-
95% of commercial compounds are absorbed primarily by passive diffusion, there is a great 
interest in rapid and inexpensive simultaneous dissolution-permeation assays.52  
Some absorption studies have been performed using artificial membranes as well. The 
most standard membrane-based assay is the parallel artificial membrane permeability assay 
(PAMPA) wherein the setup consists of 96-well microtiter plate containing hydrophobic 
filters that are saturated with lecithin – organic solvent mixtures.53,54 A double artificial 
membrane permeability assay (DAMPA) was also developed to incorporate an intracellular 
aqueous compartment between two hydrophobic artificial membranes separating the donor 
and receiver compartments. A number of studies have demonstrated the use of artificial 
membranes to study membrane flux and to evaluate formulation performance of poorly 
soluble drug compounds.23,55–57 The major limitation of these systems is, however, the 
small surface area for absorption relative to the volume for dissolution (~0.2 cm-1), 
resulting in lengthy, non-physiological experimental time scales (e.g. 16 hours with a side-




The challenge of a small surface area for absorption may be overcome by use of hollow 
fibers in the absorption module instead of flat-sheet membranes used in the earlier 
simultaneous dissolution and absorption testing systems. The ends of multiple hollow 
fibers are bundled into input and output ports. The hollow fibers are suspended in the drug 
dissolution/donor media. Either a syringe or a peristaltic pump drives the receiver fluid 
through the fiber lumen via the inlet port and out the outlet port. Drug diffusion occurs 
across the hollow fiber membrane along the concentration gradient from the donor to the 
receiver. The drug containing receiver media is continuously replaced by drug-free media, 
thereby maintaining an absorptive sink.  
Commercial hollow fibers of varying pore sizes are available (10 nm to 200 nm). For 
the application of simulating in vivo drug absorption, hollow fibers with low pore size may 
be employed to ensure diffusion of only free drug species. A hollow fiber membrane 
module was first used to simulate intestinal absorption in a multicompartmental, dynamic, 
computer-controlled model of human upper gastrointestinal tract (TIM-1).60 
Hydrodynamics in this apparatus were controlled by altering the water pressure on the 
flexible membranes containing luminal contents.60 However, most of the studies using 
TIM-1 have been reported for digestion and bioaccessibility of nutritional compounds, with 
only limited data available for evaluating pharmaceutical product performance.61 Blanquet 
et al. studied the impact of transit time and food on oral drug absorption and the results 
were consistent with the in vivo data.62 However, the complexity of the apparatus and 
lengthy experimental setup time are important limitations of using this system for 
evaluating drug performance.61 Recently, a simple system with commercial hollow fiber 




demonstrated the importance of fast absorption occurring simultaneously as dissolution of 
amorphous solid dispersion and mesoporous silica-based drug delivery systems in reducing 
the crystallization tendency in a seeded environment and ensuring more complete drug 
release, respectively.64,65 However, close packing of hollow fibers in a commercial module 
may cause shell-side boundary layer interferences, especially at low fluid flow rate, 
resulting in inconsistent mass transfer rates over time.66 Moreover, the authors did not 
optimize the operating parameters of the absorption module for absorption to take place at 
a physiological rate. 
1.2.2  Artificial Gut Simulator 
In this study, an artificial gut simulator (AGS) was developed consisting of a hollow-
fiber based absorption module suspended in a 3 mL UV-Vis spectrophotometer cuvette 
that serves as a drug donor. Receiver media is pumped continuously, first through the 
intraluminal space of the hollow fibers to maintain an absorptive sink and next, to a UV-
Vis spectrophotometer flow-through cell. The drug donor, absorption module and the flow-
through cell are all placed in a UV-Vis spectrophotometer where continuous measurements 
of drug concentration in the donor and receiver media are made. The advantages of this 
supersaturation-absorption testing system are as follows:  
• Large absorption surface area-to-donor volume ratio (> 2 cm-1) allows attainment of 
physiologically relevant absorption rate constant within reasonable experimental time.  
• A low molecular weight cut-off of hollow fibers excludes most non-bioavailable drug 
aggregates and complexes.  
• Low volume for testing (3 ml or less) is important for early-stage drug development 




• In-line, continuous measurement of drug concentration profiles in both donor and 
receiver media reduces sampling errors.  
• The operating parameters are directly controlled by the designer/operator of the 
absorption module and can be easily varied to attain physiological absorption rate 
constant for a particular drug. 
• The simple construction and easy operation lends potential to the AGS to screen 
formulations in a high-throughput manner.  
The overall goal of this dissertation is to design and validate the AGS and demonstrate its 
utility in decoupling the GI exchange processes occurring simultaneously upon ASD 
dissolution (Figure 1.2) and ultimately in predicting in vivo intestinal and plasma 
concentration-time profiles of BCS-II drug formulations. 
1.3 Chapter Descriptions 
1.3.1 Chapter 2. Introduction and Validation of the Artificial Gut Simulator using 
Caffeine 
Hypothesis 1. The theory of mass transport developed to describe drug diffusion from 
the AGS donor to receiver media across the hollow fiber membrane can be used to tune 
the AGS operating parameters to obtain an in vitro absorption rate constant that matches 
the in vivo absorption rate constant of a drug. 
Summary: The purpose of this study was to develop and validate a simultaneous 
dissolution and absorption testing tool, the ‘artificial gut simulator (AGS)’, for oral drug 
formulations. The AGS was constructed using hollow fibers and housed in a 3 mL UV 
spectrophotometric cuvette that provided a large surface area-to-volume ratio to simulate 




developed and validated using a high aqueous solubility, BCS-I model compound, caffeine. 
This model was used to optimize the AGS operating parameters to simulate physiological 
gastric emptying and caffeine absorption that was further input into a one compartment 
pharmacokinetic (PK) model. The in vivo caffeine plasma concentration-time profiles 
matched those predicted by the PK model with in vitro input from the AGS. Ultimately, 
this work provides a framework for establishing in vitro/in vivo correlation with especially 
high permeability, BCS-II supersaturating drug formulations which will be explored in the 
future studies. 
1.3.2 Chapter 3. Simultaneous Evaluation of Desupersaturation and Absorption from 
Ketoconazole Supersaturated Solutions using the Artificial Gut Simulator 
Hypothesis 2. Degree of crystallization from metastable supersaturated solutions of a 
BCS-II model compound, ketoconazole, will be lower in the AGS donor relative to a 
closed, non-sink ‘control’ as absorption depletes drug from the AGS donor, thereby 
reducing the driving force for crystallization. 
Summary: For supersaturating formulations of BCS-II compounds, which by definition 
have high intestinal permeability, a closed USP apparatus does not provide the necessary 
absorptive conditions during dissolution. To address this, an artificial gut simulator (AGS) 
has been constructed consisting of a 2.5 mL donor compartment in which a hollow fiber-
based absorption module is suspended. Drug from donor diffuses across the hollow fiber 
membrane to be absorbed by the continually flowing intraluminal receiver fluid. The 
membrane surface area and intraluminal fluid flow rate are tuned to obtain the 
physiologically observed absorption rate constant for a weakly basic, poorly water-soluble 




in the donor in pH 6.5 phosphate buffer by pH-shift method in the absence (closed system, 
control) and presence (open system, test) of an optimally or suboptimally tuned absorption 
module. Drug concentrations in the donor and intraluminal fluids were determined by in-
line UV spectroscopy. The presence of an absorptive sink reduced the supersaturated 
solution’s crystallization propensity, more so in the case of the optimally tuned AGS. This 
study demonstrates the significance of simulating absorption of drug at a physiological rate 
during dissolution studies, especially to predict the performance of formulations of BCS-
II drugs. 
1.3.3. Chapter 4: Understanding the Impact of Absorption on In Vitro Dissolution, 
Speciation and Precipitation of Amorphous Solid Dispersions 
Hypothesis 3. Drug absorption from the AGS donor can (i) enhance dissolution of 
amorphous solid dispersions as drug depletion from the donor can drive release of more 
drug from the formulation and, (ii) decrease the driving force for drug precipitation by 
decreasing the degree of supersaturation in drug donor. Also, drug bound to precipitate 
and colloidal polymer species can reduce the absorptive flux across the hollow fiber 
membrane due to a reduction in the drug’s thermodynamic activity in solution.  
Summary: Upon dissolution, amorphous solid dispersions (ASDs) of poorly water-soluble 
compounds can generate supersaturated solutions consisting of bound as well as ‘free’ drug 
species that are in dynamic equilibrium with each other. It is only the ‘free’ drug that is 
available for absorption. Drug bound to bile micelles, polymer excipient, amorphous and 
crystalline precipitate can reduce the drug solute’s thermodynamic activity to permeate; 
but they can also serve as reservoirs to replenish the free drug in solution lost to absorption. 




simultaneously, it may become quite challenging to understand which of the processes is 
leading to an increase or decrease in drug solution concentration. A closed, non-sink 
dissolution testing method used routinely, in the absence of drug removal, allows only for 
static equilibrium to exist and obscures the impact of each drug species on absorption. An 
artificial gut simulator (AGS) introduced recently consists of a hollow fiber-based 
absorption module and allows mass transfer of drug from the dissolution media at a 
physiological rate after tuning the operating parameters. ASDs of varying drug loadings 
were prepared with BCS-II model compound, ketoconazole (KTZ) and hypromellose 
acetate succinate (HPMCAS) polymer. Simultaneous dissolution and absorption testing of 
the ASDs was conducted with the AGS and simple analytical techniques were utilized to 
elucidate the impact of bound drug species on absorption. In all cases, lower amount of 
crystalline precipitate was formed in the presence of absorption relative to the non-sink 
dissolution ‘control’. However, formation of HPMCAS-bound drug species and crystalline 
precipitate significantly reduced KTZ absorption. Moreover, at high drug loading, 
inclusion of an absorption module was shown to enhance ASD dissolution. The rank 
ordering of the ASDs was significantly different when non-sink dissolution versus AGS 
was used and this discrepancy could be mechanistically elucidated by understanding drug 
dissolution and speciation in the presence of absorption. 
1.3.4. Chapter 5: A Scheme to Establish In Vitro/In Vivo Correlation with a Weakly Basic 
BCS-II Drug, Dipyridamole 
Hypothesis 4. Simulation of gastric emptying and absorption are key to predicting the 
dissolved and precipitated concentration of BCS-II drugs in vivo in the intestinal lumen 




while the latter will reduce the degree of supersaturation. Both these processes are 
essential for controlling the rate of precipitation. By accurately predicting in vivo 
precipitation using the AGS, correct predictions of systemic drug exposure can be made, 
thereby establishing in vitro/in vivo correlation. 
Summary: The objective of this study was to develop a scheme to establish IVIVC with 
weakly basic BCS-II drug, dipyridamole (DPD) using the artificial gut simulator (AGS) 
integrated with a compartment-based disposition model. The in vivo data for this study was 
obtained from previously published literature. A 3-compartment disposition model was 
developed using the plasma concentration-time profile of DPD following an intravenous 
bolus dose. The AGS consisting of a donor cell and a hollow fiber-based absorption module 
was tuned to absorb DPD saturated solution at a physiological rate constant, 0.0402 min-1, 
based on the measured Caco-2 cell monolayer permeability coefficient. The dose dumping 
technique commonly used during dissolution testing can generate excessively high initial 
supersaturation and precipitation which is not physiologically relevant. In this study, 
fractions of DPD dose were added every 15 min to the AGS donor to simulate first-order 
gastric emptying. The concentration absorbed by the hollow fiber receiver media was 
scaled up and input into the central compartment of the disposition model. The predicted 
plasma concentration-time profile matched the human in vivo profile of DPD obtained after 
oral administration of a 50 mg dose. For 30 and 90 mg oral doses, time profiles of 
concentration and fraction precipitated in the AGS donor agreed well with human duodenal 
measurements. This study introduces a method to develop IVIVC with a BCS-II drug and 


































Figure 2.1. A scheme to establish in vitro/in vivo correlation using input from a validated 
and optimized artificial gut simulator in a 1-compartment disposition model for a high 
aqueous solubility, BCS-I model compound, caffeine.  
 
2.2 Introduction 
Drug dissolution testing is a mainstay in evaluating drug formulations for drug release 
and solution-state stability afforded by various excipients during product development, 
both for quality control and as a prognostic tool for drug absorption.67–69 USP I and II 
dissolution testing apparati are closed vessels with dissolution media volumes up to 900 
mL. Significant efforts have been made towards developing buffer media whose pH, buffer 
capacity, ionic strength and bile acid composition mimic those of in vivo gastric and 
intestinal fluids assuming that, especially for Biopharmaceutical Classification System 
(BCS)-II compounds, absorption is only solubility or dissolution rate limited.38,39 If that is 
the case, one might be able to establish in vitro/in vivo correlation (IVIVC) to discriminate 




However, BCS-II compounds are often formulated as supersaturating solid forms 
(SSFs) such as high energy polymorphs, cocrystals, salts, and amorphous solid 
dispersions.18,72–74 These forms dissolve to generate solutions that are supersaturated, albeit 
metastable to rapid desupersaturation or crystallization into a stable form. Only drug in 
solution is available for absorption whereas drug in the crystalline and/or amorphous phase 
is not. In this case, absorption may be reduced due to crystallization.24,75 The rate of 
desupersaturation depends upon the concentration of drug in the media. A higher degree of 
crystallization has been observed in in vitro closed dissolution vessels compared to that 
observed in the intestinal lumen.76,77 This observation may be attributed to decreasing drug 
concentration due to absorption from the lumen, which in turn decreases the driving force 
for crystallization. Clearly, USP I and II closed dissolution testing apparati do not 
accurately predict the fate of drug upon dissolution and often underestimate the efficacy of 
SSFs.76,77 
Several membrane-based assay systems such as Parallel Artificial Membrane 
Permeability Assays (PAMPAs), side-by-side, or MicroFLUX™ (µFLUX) and 
MacroFLUX™ diffusion cells have been developed in recent years to simulate drug 
absorption.54,55,78,79 However, their small membrane surface areas prevent their utilization 
in simulating drug absorption at physiological rates.58,59 Recently, a hollow fiber-based 
simultaneous drug dissolution and absorption testing tool was introduced to facilitate rapid 
mass transfer across the membrane owing to its large surface area for absorption.80 
However, close packing of hollow fibers in a commercial module may cause shell side 
boundary layer interferences, especially at low fluid flow rate, resulting in inconsistent 




In this study we introduce a hollow fiber based simultaneous drug dissolution and 
absorption testing tool called the ‘Artificial Gut Simulator’ (AGS). Hydrophilic, poly(ether 
sulfone) (PES) hollow fibers are cut from a commercial module and arranged on a well 
spaced supporting framework to prevent shell side boundary layer interference. This 
hollow fiber-based absorption module is engineered to fit into a UV spectrometer cuvette 
to enable continuous in-line measurements of the drug dissolution media while minimizing 
sampling errors. The small volume of the cuvette enables testing in a sample sparing 
manner. As will be shown, this tool can be configured to “match” the physiological 
absorption rate constant (ka) of a drug, and hence provide a more realistic emulation of the 
drug’s “phase behavior” during dissolution and absorption.  
In the following sections, we first describe the AGS design and operation, followed by 
the theory behind its operation. We then validate the theory and demonstrate its scope using 
caffeine as a high aqueous solubility, BCS-I model compound. (Although the AGS is 
expected to be most beneficial for low solubility BCS-II drugs, it is easier to work with a 
high solubility drug to validate the theory of operation). As an application, the AGS is 
optimized to simulate physiological gastric emptying dynamics and caffeine absorption. 
The in vitro absorption data from the AGS is then input into a one-compartment 
pharmacokinetic (PK) model to predict in vivo plasma concentration-time profiles obtained 
from a previously published study 81 describing oral caffeine absorption as a function of 
gastric emptying, to establish Level A IVIVC.82 Finally, a framework for establishing 
IVIVC is presented for future studies that will explore the use of the AGS with low 

























Figure 2.2. (a) AGS consisting of a hollow fiber-based absorption module suspended 
in drug donor solution in a UV-Vis spectrophotometer sample cuvette (Scale bar: 1 division 








The AGS (Figure 2.2) consists of a) a cuvette that serves as a donor of drug 
dissolved/suspended in an aqueous medium and, b) an absorption module consisting of 
hollow fibers suspended from the lid of the cuvette, providing an absorptive sink (Figure 
2.2a). The large surface area of the hollow fibers enables attainment of physiologically 
relevant rates of mass transfer. Hollow fibers are arranged on a plexiglass supporting 
framework and their ends are bundled into inlet and outlet ports for flow of intraluminal 
buffer. Concentrations of drug in the donor/extraluminal and receiver/intraluminal media 
are determined using a UV-Vis spectrophotometer equipped with a temperature controlled 
and magnetically stirred automatic multi-cell changer (Figure 2.2b). Constant stirring 
ensures homogenous distribution of drug throughout the extraluminal medium. Buffer 
(intraluminal medium) is pumped continuously through the hollow fiber manifold using a 
syringe pump. As drug diffuses across the hollow fiber membrane from the extra- into the 
intraluminal medium, the intraluminal absorbate is continuously replaced by drug-free 
buffer, thereby maintaining an absorptive sink.  
A spectrophotometric assay of extraluminal medium in the cuvette is conducted every 
minute. Next, the concentration of drug in the intraluminal medium is determined when it 
is pumped to a flow-through cell placed in the cell slot adjacent to the donor cuvette. By 
this means, alternating absorbance measurements of extra- and intraluminal media are 
made continuously over the duration of the study. 
As will be discussed in the following sections, the operating parameters of the AGS are 











Figure 2.3. Schematic representation of AGS in operation. 
 
Figure 2.3 is a schematic representation of the AGS, which consists of a well-stirred 
donor vessel (in practice a cuvette) containing drug solution of volume V. A manifold of N 
hollow fibers, each of length L, intraluminal diameter d, and membrane permeability P to 
the drug, is introduced into the vessel as the absorption module. The manifold’s inlet is 
connected to a syringe pump, which delivers drug-free intraluminal buffer at a constant 
total flow rate, Q, and its outlet is connected to tubing leading to a detector, where the 
exiting drug concentration, 𝐶IL, is assayed. Flow through a single fiber is given by Q/N, 
and the average fluid velocity in the fiber is 𝑣 = (𝑄/𝑁)/(𝜋𝑑2/4). The uniform 
extraluminal drug concentration in the vessel, 𝐶EL, is also available for assay.  
As buffer is pumped through the manifold, free drug diffuses across the hollow fiber 
membranes into the hollow fiber lumens and is carried out of the vessel by convection.  
Assuming rapid radial mixing in the lumen, 𝑑2/𝐷 << 𝐿/𝑣, where D is the diffusion 
coefficient of drug in the luminal fluid, and also assuming that concentration gradients 










+ (𝜋𝑑)𝑃(𝐶𝐸𝐿 − 𝐶𝐼𝐿)          0 < 𝑥 < 𝐿                      (2.1) 
 
where 𝐶𝐼𝐿 = 𝐶𝐼𝐿(𝑥, 𝑡) is the local intraluminal concentration and 𝐶𝐸𝐿 = 𝐶𝐸𝐿(𝑡) is 











(𝐶𝐸𝐿 − 𝐶𝐼𝐿)  0 < 𝑥 < 𝐿                                                  (2.2)
      
We ignore axial diffusion in this development.  This assumption is justified by the long 
length of the hollow fiber relative to the short distance that a drug molecule can diffuse 
axially during its residence time in the lumen.  If we may assume that 𝐶𝐸𝐿(𝑡) changes 
slowly with time compared to 𝐶𝐼𝐿(𝑥, 𝑡), then we can invoke the quasi-steady state 











𝐶𝐸𝐿  0 < 𝑥 < 𝐿                            (2.3) 
    
At any time, the entry point of the hollow fiber is drug free, i.e. 𝐶𝐼𝐿(0, 𝑡) = 0 and 
𝐶𝐼𝐿𝑞𝑠𝑠(0, 𝑡) = 0.  Combining the latter boundary condition with Eq. (2.3), we obtain 
 
 𝐶𝐼𝐿𝑞𝑠𝑠(𝑥, 𝑡) = 𝐶𝐸𝐿(𝑡) [1 − 𝑒𝑥𝑝 (−
4𝑃𝑥
𝑣𝑑






In particular,  
 
 𝐶𝐼𝐿𝑞𝑠𝑠(𝐿, 𝑡) = 𝐶𝐸𝐿(𝑡) [1 − 𝑒𝑥𝑝 (−
4𝑃𝐿
𝑣𝑑
)]       (2.5) 
 
Substituting for v and considering the intraluminal surface area of each hollow fiber, 𝐴𝐼𝐿 =
𝜋𝑑𝐿, the latter equation takes the form 
 
 𝐶𝐼𝐿𝑞𝑠𝑠(𝐿, 𝑡) = 𝐶𝐸𝐿(𝑡) [1 − 𝑒𝑥𝑝 (−
𝑁𝑃𝐴𝐼𝐿
𝑄
)]                  (2.6) 
 
At quasi-steady state the rate of drug removal from the AGS is 𝑄𝐶𝐼𝐿𝑞𝑠𝑠(𝐿, 𝑡) , hence 





= 𝑄 [1 − 𝑒𝑥𝑝 (−
𝑁𝑃𝐴𝐼𝐿
𝑄
)]                  (2.7) 
 
When drug is introduced into the donor (extraluminal) medium at time 𝑡 = 0 at 
concentration 𝐶EL(0) at or below saturation, its concentration 𝐶EL(𝑡) will decay according 
to 
               𝐶EL(𝑡) = 𝐶EL(0)𝑒










) [1 − 𝑒𝑥𝑝 (−
𝑁𝑃𝐴𝐼𝐿
𝑄





is the apparent “absorption rate constant” of the AGS, which can be matched to the target 
physiologic value (𝑘a) by varying the parameters in the RHS of Eq. (2.9). 
Of particular interest in this design is that one can work with small vessel volumes. 
Reduction of donor volume can be compensated by reducing absorption clearance to obtain 
the target 𝑘a. As long as the in vivo and in vitro dose-to-volume ratios are matched, one 
need not work with USP sized dissolution vessels or even intestinal luminal volumes (as 
in the case of TIM gastrointestinal systems 83).  Thus studies can be carried out in a sample 
sparing manner. 
It is useful to explore certain limits.  In the flow-limited case, where 𝑄 << 𝑁𝑃𝐴IL, 
𝑘a,AGS approaches 𝑄/𝑉, whereas in the opposite, permeation-limited case where 𝑄 >>
𝑁𝑃𝐴IL, Taylor expansion of Eq. (2.9) yields 𝑘a,AGS → 𝑁𝑃𝐴IL/𝑉. Consideration of these 
limits enables the operator to select, for example, the number of hollow fibers (N) and the 
flow rate (Q) once the other parameters are determined. 
 
2.5 Materials and Methods 
2.5.1 Materials 
Caffeine was purchased from Fisher Scientific International, Inc. (Fair Lawn, NJ) and 
was used as received. 50 mM sodium phosphate buffer, pH 6.5, was used as the aqueous 
medium in the extra- and intraluminal media. 
To construct the absorption module, 1.5 mm thick plexiglass was laser cut and welded 
into a hollow fiber supporting framework. PES hollow fibers of 5 kDa MWCO (molecular 




module purchased from Spectrum Laboratories Inc. (C06-E005-10-N, Rancho Dominguez, 
CA). Cuvette caps were purchased from Azzota Scientific (Claymont, DE). UV-cure 
silicone glue, used as potting material to fix the hollow fibers in the inlet and outlet tubes 
emerging from the cuvette cap, was purchased from Henkel Corporation (Westlake, OH). 
2.5.2 Caffeine Permeability Coefficient across PES Hollow Fiber Membrane 
Mass transport of caffeine across PES hollow fiber membranes from solutions at 
different sub-solubility concentrations was evaluated using the AGS setup shown in Figure 
2.2. 50 mM pH 6.5 phosphate buffer was pumped at Q=160 µL/min into the intraluminal 
space of N=5 hollow fibers in the absorption module using a syringe pump. Caffeine 
solutions of concentrations 20, 30, 40, 50 and 60 µg/mL were prepared separately in 50 
mM pH 6.5 phosphate buffer. In a given run, V=2.5 mL of a particular solution was 
introduced into the donor cuvette at 37℃, at time t=0. Drug concentration in the 
extraluminal fluid was continuously monitored by UV spectrophotometry (Cary 100 Bio, 
Agilent, CA) at 278 nm for 120 min. Runs for each concentration of caffeine were carried 
out in duplicate.  The permeability coefficient, P, of caffeine cross the PES membrane was 
estimated by fitting the experimental donor concentration-time profiles to Eq. (2.8) and 
then using Eq. (2.9).   
2.5.3 Theoretical Model Validation  
Theoretical model predictions describing mass transport of solute across the hollow 
fiber membrane were validated against the experimental caffeine extra- and intraluminal 
concentration-time profiles obtained by varying the operating parameters of the AGS. The 
permeability coefficient estimate of caffeine obtained from the previous experiment was 




was prepared in 50 mM pH 6.5 phosphate buffer and introduced into the cuvette as the 
donor drug solution. Volume of the donor drug solution was 2.5 mL. In the first test, drug-
free pH 6.5 phosphate buffer was pumped into hollow fiber modules of three different total 
surface areas for absorption, 9.42, 6.28 and 3.14 cm2 (corresponding to N = 6, 4, and 2 
hollow fibers) while maintaining a constant pumping rate through each fiber. In the second 
test, intraluminal fluid was pumped at three different flow rates, 40, 80 and 160 μL/min 
through a hollow fiber module of surface area 9.42 cm2 (N= 6). A summary of the 
experimental design is given in Table 2.1. Absorbance measurements from the donor 
(extraluminal fluid) and the flow through (intraluminal fluid) cells were taken every minute 
at 278 nm. Measurements were conducted in duplicate. 
 
Table 2.1. Experimental design to validate AGS theoretical model. The operating 
parameters, surface area of hollow fibers and intraluminal fluid flow rate through each 









2.5.4 Simulating In Vivo Absorption of Caffeine using the AGS 
As an application, the AGS was used to simulate a previously published case study81, 
in which the time dependent oral absorption of caffeine in humans was correlated with 
gastric motor activity. In that in vivo study81, 100 mg doses of caffeine in the form of enteric 
coated pellets were administered to subjects so that caffeine absorption occurred only in 
the intestine. Absorption of caffeine was a function of the measured gastric motor activity 
in each individual subject, which directly influenced gastric emptying of caffeine into the 
small intestine. Subjects  4, 5 and 6 (out of 12 total subjects) from the study were considered 
here to approximately represent the range of gastric emptying dynamics.  In vivo data was 
extracted from figures using WebPlotDigitizer (https//apps.automeris.io/wpd/).  
Parameters from Ref. [81] are summarized in Table 2.2. 
The study revealed large inter-individual differences with complicated gastric motor 
activity-time profiles and time-dependent gastric emptying rate constant k
g,n
 (t) (‘n’ 
indexing the phase of gastric motility) (Table 2.2). Gastric emptying occurred following an 
initial quiescent phase lasting 1-2 hours. This was followed by an active phase during 
which more than 50% of the dose administered was emptied in a first-order manner. More 
than 90% of the dose was emptied from the stomach in the next 2 hours with one or two 
more quiescent periods between the active phases. There were also inter-subject 
differences in caffeine absorption rate constant.  Absorption rate constant (𝑘𝑎) values 
varied from 0.029 – 0.089 min-1. Assuming 100 mL intestinal volume, the in vivo dose-to-
intestinal volume ratio (𝐷𝑖𝑛 𝑣𝑖𝑣𝑜: 𝑉𝑖𝑛 𝑣𝑖𝑣𝑜)  was 1 mg/mL. 
The volume of extraluminal, pH 6.5 phosphate buffer used as donor fluid in the in vitro 




concentrated stock solution containing 2.95 mg caffeine in 10 L pH 1.5 HCl buffer was 
prepared. Fractions of this stock solution were spiked into the extraluminal buffer at times 
corresponding to the start of active phases of gastric motility, as summarized in Table 2.2. 
(An enteric coated formulation was not used here as it was stipulated in the human in vivo 
study that the enteric coating and drug dissolution in the intestine was rapid81.)  
Table 2.2. Summary of caffeine in vivo parameters used as inputs in the PK model and in 
vitro dosing schedule to simulate gastric emptying with AGS for subjects 4, 5 and 6 in Ref. 
[81].  k
g,n
 (t), gastric emptying rate constant during the n’th phase of gastric motility; k
a
 , 
absorption rate constant; k
e
 , elimination rate constant; V
d
 , volume of distribution; D
in vivo
, 
in vivo dose administered; V
in vivo 
, in vivo intestinal volume; D
in vitro 
, in vitro Dose; V
in vitro
, 





To account for the differing values of 𝑘𝑎 observed across subjects, hollow fiber module 
parameters, specifically intraluminal fluid flow rate, Q, and number of hollow fibers, N  
(therefore, surface area of the follow fibers) were varied to obtain the desired 𝑘𝑎,𝐴𝐺𝑆         
[Eq. (2.9)] for each subject. Caffeine concentration in the intraluminal fluid was measured 
by UV spectroscopy every minute. The high caffeine concentration in the donor medium 
saturated the spectrophotometer and could not be measured.  
To investigate IVIVC, a one-compartment PK model for drug in plasma was set up in 
SimBiology (MATLAB R2020b). The parameters, elimination rate constant, 𝑘𝑒 and 
volume of distribution, 𝑉𝑑 reported in the in vivo study 
81 are summarized in Table 2.2 for 
subjects 4, 5 and 6 and were used as inputs for the PK model. The in vitro drug 
concentration absorbed by the intraluminal fluid, 𝐶𝐼𝐿(𝐿, 𝑡), was used to generate an input 
function 𝐼(𝑡) to describe the in vivo amount of drug absorbed with time [Eq. (2.10)]. 
𝐼(𝑡) =  𝐶𝐼𝐿(𝐿, 𝑡) × 𝑄 × 𝑡𝑖𝑚𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡𝑠 ×
𝐷𝑜𝑠𝑒𝑖𝑛 𝑣𝑖𝑣𝑜
𝐷𝑜𝑠𝑒𝑖𝑛 𝑣𝑖𝑡𝑟𝑜
           (2.10)  
Ultimately, 𝐼(𝑡) was input into the PK model to predict the in vivo plasma-concentration 
time profile of caffeine [Eq. (2.11)] and establish Level A IVIVC:  
 
 





















Figure 2.4. Donor drug concentration-time plots at five different starting concentrations of 
caffeine. Error bars represent standard deviations of duplicate measurements. The 
experimental data sets were fit to Eqs. (2.8) and (2.9) (black lines) to obtain average 𝑃. 
 
The caffeine mass transfer study across the hollow fiber membrane was conducted using 
concentrations at sub-solubility levels in pH 6.5 phosphate buffer at 37 ℃. The AGS was 
operated at an intraluminal fluid flow rate of 160 µL/min, hollow fiber area for absorption 
of 7.85 cm2 (N=5) and donor volume of 2.5 mL for all the runs. Figure 2.4 shows the 
cumulative donor (extraluminal) concentration-time profiles of caffeine obtained from 
continuous UV spectrophotometric measurements. The donor drug concentration 
decreased in all cases due to absorption across the hollow fiber membrane into the 
intraluminal buffer. The decline in donor drug concentration due to absorption was 
exponential and after 120 minutes, about 95% of the drug was cleared from the donor 
solution. Membrane permeability, 𝑃, was estimated by fitting the respective donor 









































concentration-time series obtained to Eq. (2.8) and then using Eq. (2.9). From these curves 
𝑃  was estimated to be (2.34 ± 0.02) × 10−4 cm/s. 
 












Figure 2.5. Predicted [Eqs. (2.8) and (2.6), respectively; lines] and experimental 
(symbols) concentrations of extraluminal and intraluminal caffeine. (a) Extraluminal 
and (b) intraluminal concentration-time plots obtained by varying intraluminal fluid 
flow rate, Q,  through a hollow fiber module of surface area 9.42 cm2 (N = 6).                  
(c) Extraluminal and (d) intraluminal concentration-time plots obtained by varying N, 
the number of hollow fibers (in other words, total hollow fiber surface area), while 
maintaining a constant intraluminal fluid flow rate of approximately 27 µL/min 





Using the value of permeability, 𝑃, estimated in the previous section, the theoretical model 
developed was validated by monitoring caffeine mass transport across the hollow fiber 
membranes from an initial 40 µg/mL solution in the donor into the intraluminal buffer. As 
summarized in Table 2.1, the AGS was operated at different flow rates and surface areas 
for absorption (i.e. numbers of hollow fibers). The resulting extra- and intraluminal 
concentration-time profiles predicted using Eqs. (2.8) and (2.6), respectively, are 
represented as solid lines corresponding to their respective experimental data sets 
(symbols), all plotted in Figure 2.5.  Under all conditions, donor caffeine concentration 
declines exponentially with time due to drug absorption (Figure 2.5a,c).  The intraluminal 
drug concentration, on the other hand, initially increases from zero, but eventually tips over 
and decays exponentially (Figure 2.5b,d). This behavior can be attributed to a combination 
of delay in attaining quasi-steady state due to the residence time of buffer in the hollow 
fiber and an initial diffusional time lag across the hollow fiber membrane. Following 
attainment of quasi-steady state, drug concentration in the intraluminal fluid decreases as 
the driving force for permeation across the hollow fibers decreases with declining donor 
concentration. Experimental data of donor and intraluminal concentrations are in excellent 
agreement with predictions in all cases, except during the initial time points before 
attainment of quasi-steady state in the intraluminal fluid.  
In Figure 2.5a,b  (constant N with varying Q) it is shown that upon attainment of 
quasi-steady state, extra- and intraluminal drug concentrations decline more rapidly as the 
intraluminal fluid flow rate increases due to better sink conditions. At lower flow rates, the 
time lag to attain quasi-steady state is longer. Time lags can be expected to increase with 




boundary layers adjacent to the intraluminal membrane. 66 (This contradicts our assumption 
of rapid radial mixing in the hollow fiber.) While drug clearance from the donor increases 
considerably as we increase the intraluminal fluid flow rate from 40 to 80 µL/min, the 
increase in clearance is more modest upon further increase in flow rate, indicating that we 
are close to the permeation-limited absorption regime wherein 𝑄 >> 𝑁𝑃𝐴IL, and the 
magnitude of 𝑘a,AGS is dependent only on 𝑁, 𝐴IL, 𝑃 𝑎𝑛𝑑 𝑉.  
At constant intraluminal flow rate per hollow fiber (Q/N), as surface area for absorption 
increases with increasing number of hollow fibers in the absorption module, the rate of 
drug absorption from the donor also increases (Figure 2.5c). Since the intraluminal fluid 
flow rate through each hollow fiber is kept constant, the residence time in the hollow fiber 
lumen is the same irrespective of the number of fibers employed, which explains the 
observation of similar time-lags to attain quasi-steady state in all three cases (Figure 2.5d). 
After this, however, the rate of decline of intraluminal drug concentration is different, the 




























Figure 2.6. Family of plots of 𝑘𝑎,𝐴𝐺𝑆 of caffeine as a function of hollow fiber surface area 
for absorption (𝑁 ∗ 𝐴𝐼𝐿, 1.35 – 10.80 cm
2) and receiver fluid flow rate (𝑄, 0 – 2 mL/min) 
obtained using Eq. (2.9). AGS operating parameters were optimized for each subject to 
obtain the respective target 𝑘𝑎. Volume of extraluminal fluid, V, was fixed at 2.95 mL.  
Hollow fiber (HF) membrane permeability, P,  was fixed at 2.34  10-4 cm/sec. 
 
To simulate each subject 4, 5 and 6 in the in vivo study81, the AGS was tuned, using             
Eq. (2.9) and varying 𝑄 and 𝑁, to absorb caffeine according to that subject’s 
physiologically observed rate constant, 𝑘𝑎 (Table 2.2). Figure 2.6 is a family of curves 
showing how 𝑘𝑎,𝐴𝐺𝑆 increases with increasing 𝑄 and 𝑁, given the permeability of the HF 
membrane and the volume of the extraluminal fluid.  Using these curves, one can select 𝑄 























Figure 2.7. (Left) Intraluminal caffeine concentration-time profile as caffeine was 
absorbed from the donor medium. Peaks represent the points of addition of caffeine dose 
fraction to simulate gastric emptying (Table 2.2) in subjects 4, 5 and 6. (Right) Overlaid 
in vivo81 (filled black circles) and predicted (mean, open magenta squares) plasma 
concentration-time profiles predicted using the one-compartment PK model with AGS in 




Figure 2.7 (left) shows, for each of the simulated subjects, the intraluminal 
concentration-time profile as caffeine was absorbed from the donor medium, i.e. the 
cuvette. Varying fractions of the caffeine dose were added to the donor at varying times to 
correspond to the fraction of drug emptied in vivo from the stomach into the small intestine 
during the active phases of gastric motility in the three subjects (Table 2.2). Upon addition 
of caffeine, after a certain diffusional time lag, maximum drug concentration (𝐶𝑚𝑎𝑥) and 
quasi-steady state were attained in the intraluminal media and this occurred each time a 
dose addition was made. With time, the concentration of drug decreased in the donor due 
to absorption and this is reflected in the declining drug concentration in the intraluminal 
fluid following each 𝐶𝑚𝑎𝑥. (The sudden decline in drug concentration at each point of 
addition of drug dose fraction is due to the removal of the AGS absorption module from 
the donor media resulting in absence of drug absorption, and dilution of intraluminal drug 
concentration, for about two minutes.)  
The intraluminal concentrations were used to calculate 𝐼(𝑡) to be input into the one-
compartment PK model, Eq. (2.10), and predict caffeine in vivo plasma concentration-time 
profiles for the three subjects, Eq. (2.11). From Figure 2.7 (right), it is apparent that 










Passive permeability across the intestinal epithelial bilayer membrane plays a crucial 
role in determining the bioavailability of orally administrated drugs. However, USP I and 
II dissolution testing apparati, most commonly used to evaluate drug product performance, 
lack an absorptive sink similar to that existing in vivo. In the absence of drug removal by 
absorption, the SSFs of BCS-II drugs, which by definition have good intestinal 
permeability, precipitate under the unphysiological non-sink conditions of these closed 
dissolution testing apparati.76 High drug concentration above drug solubility serves as a 
driving force for precipitation and an unrealistic degree of supersaturation can ultimately 
lead to poor IVIVC. This is unlike the condition that exists in the small intestine where 
absorption decreases drug concentration in the intestinal lumen, which in turn decreases 
the driving force for crystallization.77,84 
Le Chatelier’s principle states that if a physicochemical system in dynamic equilibrium 
experiences a change in concentration of the reactants or products, the system will respond 
to oppose that change. This means that declining drug concentration in the intestinal lumen 
due to absorption will cause precipitate formed to redissolve to replenish the drug in 
solution lost to absorption.25 By the same principle, even when drug dissolution from a 
formulation is the rate-limiting step in drug absorption, more drug can be expected to be 
released in a system with an absorptive sink in comparison to one without. Thus, an in vitro 
testing tool that can simulate the in vivo intestinal luminal conditions not just in terms of 
the luminal dissolution media but also absorption rate, is needed.  
The AGS was engineered to provide a high surface area-to-dissolution volume using 




spectrophotometer cuvette as a dissolution vessel allows in-line continuous measurements, 
preventing sampling errors. Moreover, the small volume of the cuvette enables testing to 
occur in a high throughput, sample sparing manner, which is convenient during early-stage 
drug development.  
The present study presents and validates a theory of concentration gradient-driven mass 
transport of a drug solute from the dissolution media into the buffer in the lumen of the 
hollow fiber using a quasi-steady state model. The ultimate parameter of interest, 𝑘𝑎,𝐴𝐺𝑆, 
can be ‘dialed in’ to match the target 𝑘𝑎 and simulate drug absorption at a physiological 
rate by varying intraluminal fluid flow velocity, surface area of absorption, and dissolution 
volume. The parameter 𝑃 was determined by fitting Eqs. (2.8) and then (2.9) to 
extraluminal concentration-time profiles obtained for various starting concentrations of 
caffeine (Figure 2.4). This allowed the estimation of 𝑘𝑎,𝐴𝐺𝑆 of caffeine for a set of 
operating parameters of the AGS using Eq (2.9). Eqs. (2.8) and (2.6), respectively, 
predicted quasi-steady state exponential decline in drug concentration in the extra- and 
intraluminal media, thereby validating the model (Figure 2.5).  
Typically, 𝑘𝑎 is not known, especially for drugs in early stages of development. Mudie 
et al. have reviewed the importance of simulating 𝑘𝑎 during in vitro dissolution and 
absorption testing and how it can be estimated for drugs for which 𝑘𝑎 is unknown a priori.
36 
Briefly, in vivo 𝑘𝑎 is a function of the permeability coefficient of the drug across the 
intestinal epithelial membrane, 𝑃𝑒𝑚, and the geometric surface area of the intestine-to-











𝑃𝑒𝑚 can be estimated using models that use molecular descriptors as input parameters for 
passively absorbed drugs.85 Alternatively, 𝑃𝑒𝑚 can be estimated using Caco-2 cell 
monolayer or rat perfusion assays.85 Mudie et al. divided the 𝑘𝑎 values of passively 
absorbed drugs in humans by their respective 𝑃𝑒𝑚 values estimated using molecular 
descriptors and estimated 
𝑆𝐴
𝑉𝑖𝑛 𝑣𝑖𝑣𝑜




estimates of 𝑃𝑒𝑓𝑓 obtained using ex vivo assays or molecular descriptors, 𝑘𝑎 of a compound 
may be estimated. The AGS operating parameters can then be optimized using Eq. (2.9) to 
simulate drug absorption at the desired 𝑘𝑎. 
As a case example drawn from Ref. [81], in vivo absorption of caffeine was simulated 
using the AGS optimized to absorb drug at three different absorption rates as determined 
for three different subjects. Typically, a single average absorption rate constant for a drug 
would be determined, which can be used to optimize the AGS. However, in this study, we 
sought to demonstrate the scope of the AGS in terms of its flexibility to modify the 
operating parameters to simulate the desired absorption rate constant. Hence, the AGS was 
optimized to simulate absorption at three different absorption rate constants (corresponding 
to three subjects) for the same drug, caffeine (Figure 2.6). The AGS donor medium 
simulates the intestinal luminal fluid in terms of its pH and drug concentration. Ideally, 
both the intestinal luminal and AGS donor volumes would be set to equal. However, as 
long as 𝐷𝑖𝑛 𝑣𝑖𝑣𝑜: 𝑉𝑖𝑛 𝑣𝑖𝑣𝑜 and 𝐷𝑖𝑛 𝑣𝑖𝑡𝑟𝑜: 𝑉𝑖𝑛 𝑣𝑖𝑡𝑟𝑜 are the same, that need not be the case. Since 
𝑉𝑖𝑛 𝑣𝑖𝑡𝑟𝑜 of AGS was about 34 times lower than 𝑉𝑖𝑛 𝑣𝑖𝑣𝑜 (assumed to be 100 mL), 𝐷𝑖𝑛 𝑣𝑖𝑡𝑟𝑜 




was simulated by dosing the same fraction of drug as was emptied during the active phases 
of gastric mobility (Table 2.2). Concentration of drug absorbed was measured in the 
intraluminal fluid and was scaled up to generate an input function I(t) [Eq (2.10)]. 
Ultimately, I(t) was used to input the dose amount absorbed in the one-compartment 
caffeine disposition model [Eq (2.11)]. 
For BCS-I drugs, gastric emptying is an important rate-limiting step for absorption. 
Since gastric emptying may be discontinuous, it is not uncommon to observe multiple 
peaks in the plasma concentration-time course.86 This was observed in subjects 4 and 6 and 
this discontinuous gastric emptying was similarly simulated in vitro using the AGS. In all 
the cases, the one-compartment PK model was able to predict the in vivo caffeine plasma 
concentration-time courses with good accuracy (Figure 2.7).81  
In a more generalized case, it may be possible to simulate gastric emptying by 
introducing the drug pre-dissolved/suspended in simulated acidic gastric media into the 
simulated intestinal media (having the absorption module) at a first order rate constant (2.8 
hour-1) using a programmable syringe pump.87 This is especially important for introducing 
SSFs of BCS-II compounds as the rate of gastric emptying, or in other words, the rate of 
drug introduction into the simulated intestinal media, influences the rate of supersaturation 
generation, which in turn influences the rate of drug crystallization.88  
Below is a step-wise framework that be utilized for the establishment of IVIVC using 
the AGS. 




2. Determine human 𝑘𝑎 either directly from in vivo studies or indirectly using molecular 
descriptor model or ex vivo assays to determine 𝑃𝑒𝑚 [Eq. (2.12)]. 
3. Use the theory developed in this study [Eq. (2.9)] to tune the AGS to simulate 
absorption at physiological 𝑘𝑎.  
4. Determine 𝐷𝑖𝑛 𝑣𝑖𝑣𝑜: 𝑉𝑖𝑛 𝑣𝑖𝑣𝑜 and match it to 𝐷𝑖𝑛 𝑣𝑖𝑡𝑟𝑜: 𝑉𝑖𝑛 𝑣𝑖𝑡𝑟𝑜. 
5. Conduct simultaneous dissolution/absorption testing by either introducing the drug as 
a single bolus or at a first-order rate to simulate gastric emptying. 
6. Measure the intraluminal concentration-time profile and determine the cumulative 
fraction absorbed as a function of time. 
7. Develop a PK model that can predict the in vivo plasma concentration-time profile of 
the drug. Then compare the PK model predictions of in vivo and in vitro percentage 
absorbed-time profiles obtained using the AGS to establish Level A IVIVC.  
8. Alternatively, in vitro AGS intraluminal concentration absorbed-time profiles can be 
scaled-up [Eq. (2.10)] and input into the PK model to predict in vivo plasma 
concentration-time courses [Eq. (2.11)]. The predicted and actual in vivo plasma 













This study introduces a novel, convenient and inexpensive in vitro dissolution and 
absorption testing tool. Compared to flat-sheet membranes used in diffusion cells, the 
surface area for absorption in the AGS was greatly increased by using hollow fibers. A 
theory of mass transport from the donor media into the continuously flowing hollow fiber 
luminal buffer was developed and validated using caffeine. The importance of simulating 
drug absorption at physiological 𝑘𝑎 was highlighted and the AGS operating parameters 
were tuned to attain the same with caffeine. Caffeine plasma concentration-time courses 
predicted by the PK model using in vitro AGS absorption data as input were demonstrated 
to match in vivo profiles. The next step would be to understand how inclusion of such an 
absorption module may influence supersaturated formulation precipitation kinetics and 
whether there is an improvement in IVIVC in comparison to that obtained using a closed 























Chapter 3: Simultaneous Evaluation of Desupersaturation and Absorption from 




























Figure 3.1 Schematic representation of simultaneous absorption, amorphous and 
crystalline precipitation from a single phase supersaturated solution of a BCS-II compound. 
Crystalline and amorphous phases can redissolve to replenish the free drug in solution lost 
to absorption, with the latter redissolving at a much faster rate due to higher free energy 
and larger surface area in contact with the aqueous media. 
 
3.2 Introduction 
Over the past three decades, high-throughput screening has resulted in a discovery 
pipeline consisting mostly of highly potent but lipophilic, relatively large molecular weight 
compounds exhibiting poor aqueous solubility and largely classified as Biopharmaceutics 
Classification System (BCS) Class II.89,90 Since poor solubility limits absorption and 
bioavailability, there have been many efforts to enhance the apparent solubility of such 




concentrations exceeding thermodynamic solubility, have received much attention. 
Supersaturating solid forms (SSFs) include high energy polymorphs, cocrystals, salts, and 
amorphous solid dispersions (ASDs).18,73,74,91 When dissolved at supersaturating solution 
concentrations, higher thermodynamic activity of the drug solute (relative to that of a solute 
at equilibrium with the crystalline phase) translates to an increased driving force for transit 
from the intestinal lumen into and through enterocytes.92–95 However, phenomena such as 
salt disproportionation or amorphous-to-crystalline and polymorphic phase transformation 
can also occur with SSFs during manufacturing, storage, or dissolution into the intestinal 
fluid, partially canceling the intended benefit.71,96–99 
To mechanistically understand and discriminate between the performance of SSFs, in 
vitro, and ultimately predict their performance in vivo, there is a need to develop tools that 
closely simulate conditions existing in the gut. Traditionally, the most common tool has 
been the standard USP dissolution test, with periodic withdrawal and analysis of liquid 
aliquots. With respect to SSFs, drug precipitates are excluded during analysis, and a 
“spring-parachute” dissolution profile is often observed, with the “spring” corresponding 
to rapid dissolution of drug into the supersaturated state, followed by the “parachute,” 
during which some of the drug crystallizes.88,100 
A highly supersaturated drug solution can also undergo glass-liquid or liquid-liquid 
phase separation (LLPS), that is, amorphous precipitation prior to drug crystallization to 
form drug rich disordered colloidal aggregates.101,102 Such behavior is observed when drug 
concentration exceeds its amorphous solubility in the aqueous medium. These aggregates, 
unlike the crystalline phase, are thought to be in dynamic equilibrium with drug in solution, 




metastable supersaturated solution can eventually overcome the kinetic barrier to crystal 
nucleation, decreasing the drug solution concentration.  
The standard USP dissolution test is neither optimal nor satisfactory in predicting the 
performance of SSFs. The system is ‘closed’ with respect to released drug, and any effects 
of drug absorption, which will tend to lower drug concentration in the intestinal fluid and 
subsequently reduce the driving force for crystallization, are suppressed.76,84,103,104 In this 
sense, the standard dissolution test may be more stringent than necessary, underestimating 
efficacy, especially for BCS-II drugs which, by definition, have good intestinal 
permeability properties. Prediction of drug precipitation effects, amorphous and/or 
crystalline, on drug release and bioavailability can be made by combining in vitro data with 
computational modeling of drug absorption103,104 or by using in vitro tools that allow 
continuous drug removal from the dissolution media at physiologically relevant absorption 
rates.105 The latter would likely be more insightful into the solution phase behavior of the 
drug.  
An inexpensive, rapid and material-sparing screening tool called the ‘Artificial Gut 
Simulator (AGS),’ which simulates drug absorption using a hollow fiber-based absorption 
module with a large surface area was developed in Chapter 2. The absorption module is 
suspended in a UV spectrophotometer cuvette containing the donor medium. Drug in the 
donor medium diffuses across the hollow fiber membrane into the intraluminal receiver 
fluid, which is replaced continuously by fresh buffer, thereby maintaining an absorptive 
sink. Operating parameters of the AGS such as the surface area of hollow fibers, 
intraluminal fluid flow rate and volume of donor medium, are directly controlled by the 




rate constant of a drug under study when that drug is present at or below saturation. Under 
these conditions, drug concentration in the AGS is expected to decline exponentially, 
according to the “dialed in” rate constant. When drug is introduced into the AGS at 
supersaturated concentrations, processes such as crystallization and LLPS may be signaled 
by deviations from exponential decline in free drug concentration in the AGS.  
In the present study, the AGS is tuned to simulate absorption of the model drug 
ketoconazole (KTZ). KTZ is a low solubility, high permeability BCS Class II drug. Upon 
oral administration as an SSF, ionization and aqueous solubility of weakly basic KTZ 
decreases as it is emptied from the acidic stomach into the relatively alkaline intestinal 
environment, resulting in a supersaturated solution.77 KTZ is classified as a slow 
crystallizer, a highly supersaturated solution of which can experience LLPS.106 The pH-
shift method was therefore used here to generate supersaturated solutions of KTZ in the 
donor compartment of the AGS at concentrations above and below its amorphous 
solubility. Drug precipitation was studied as absorption occurred simultaneously. To 
demonstrate the need for simulating drug removal at its physiological rate, absorption of 
drug from supersaturated KTZ solution was conducted using optimized and sub-optimal 
AGS operating parameters. The key expectation was that the extent of crystallization from 
KTZ supersaturated solution is relatively low when drug is absorbed from the donor at the 
biorelevant rate. In systems with lower absorption rates or no absorption at all, the driving 
force for KTZ crystallization increases, decreasing the flux across the hollow fiber 






3.3 Material and Methods 
3.3.1 Materials 
KTZ was donated by Laborate Pharmaceuticals (Haryana, India) and was used as 
received. 50 mM sodium phosphate buffer, pH 6.5, was prepared using monobasic sodium 
phosphate monohydrate and dibasic sodium phosphate heptahydrate, both purchased from 
Sigma-Aldrich Inc., MO and used as the aqueous medium in the donor and receiver. 
Hydrochloric acid (36.5 – 38.0%) was purchased from Sigma-Aldrich Inc., MO and used 
as received.  
AGS absorption module was constructed per a method described earlier (Chapter 2). 
Briefly, modified polyethersulfone (mPES) hollow fibers were cut from a filtration module 
purchased from Spectrum Laboratories Inc. (C06-E005-10-N, Rancho Dominguez, CA), 
placed in a laser-cut plexiglass supporting framework and potted into the inlet and outlet 
tubes emerging from the cuvette cap (Azzota Scientific, DE) using a UV cure silicone glue 
(Henkel Corporation, OH). The hollow fibers used here had L=5 cm, d=1 mm and 
molecular weight cut-off (MWCO) of 5 kDa. 
3.3.2 Crystalline and Amorphous Solubility of KTZ 
The crystalline solubility of KTZ in 50 mM sodium phosphate buffer at pH 6.5 was 
determined by equilibrating excess solid drug in aqueous medium for 48 hours at 37℃. 
Undissolved solids were separated by centrifugation in a Marathon 26KMR 
microcentrifuge (Thermo Fisher Scientific Inc., MA) at 14,800 rpm for 60 min. KTZ 
concentration in the supernatant was measured by UV spectroscopy (Cary 100 Bio, Agilent 




Amorphous solubility was determined using a method described previously.102 
Solubilized KTZ (6 mg/mL) in pH 1.5 HCl was titrated into pH 6.5 phosphate buffer at a 
rate of 10 μL/min. Titration was performed in a 3 mL quartz cuvette at 37℃ under constant 
stirring. Light scattering by phase separated KTZ was monitored by UV spectroscopy at a 
non-absorbing wavelength of 312 nm. The onset of UV-extinction at 312 nm indicated the 
appearance of LLPS and the corresponding concentration was taken to be the amorphous 
solubility of KTZ. pH of the solution after titration was 6.43.  KTZ standard solutions (1 - 
140 μg/mL) were prepared in pH 6.5 phosphate buffer with pre-dissolved 3 mg/mL (2-
hydroxypropyl)-β-cyclodextrin (Sigma Aldrich, MO). Standards and samples were 
analyzed in triplicate. 
3.3.3 Polarized Light Microscopy 
To characterize the dispersed phase, 66 μL of solubilized KTZ in pH 1.5 HCl solution, 
at concentrations of 0.75 mg/mL and 3.79 mg/mL, was added to 3 mL pH 6.5 phosphate 
buffer to generate solutions with concentrations below (20 µg/mL) and above (100 µg/mL) 
the LLPS onset concentration, respectively. A small aliquot of the solution (containing the 
dispersed phase) was placed between a glass slide and a coverslip and was observed using 
a polarized light microscope at 40x magnification (Eclipse E200, Nikon Co., Tokyo, 
Japan). 
3.3.4 KTZ Permeability Coefficient across PES Hollow Fiber Membrane 
Mass transport of KTZ across PES hollow fiber membranes from solutions at different 
sub-solubility concentrations was evaluated using the AGS. 50 mM pH 6.5 phosphate 
buffer was pumped at 160 µL/min flow rate into the intraluminal space of 5 hollow fibers 




5.5 µg/mL were prepared separately in 50 mM pH 6.5 phosphate buffer. Then, 2.5 mL of 
each solution was added to the donor cuvette and runs were conducted in triplicate for 120 
minutes at 37℃. Drug concentration in the extraluminal fluid was continuously monitored 
by taking UV spectrophotometric measurements at 225 nm. The permeability coefficient, 
P, of KTZ across the PES membrane was estimated by fitting the experimental donor 
concentration (𝐶EL)-time (𝑡) profiles to Eq. (3.1) and then using Eq. (3.2) (based on the 
theory developed in Chapter 2). 
𝐶EL(𝑡) = 𝐶EL(0)𝑒
−𝑘a,AGS𝑡 (3.1) 




) (1 − 𝑒
−
𝑁𝑃𝐴IL
𝑄 ) (3.2) 
is the apparent “absorption rate constant” of the AGS, which depends on the number of 
hollow fibers (N), receiver fluid flow rate (Q), and volume of the extraluminal fluid (V). 
The term 𝐴IL represents the intraluminal surface area of a single hollow fiber, which is 
determined by its length and inner diameter. For the experiments determining P, the 
following parameter values were operative: N=5, Q=160 µL/min, V=2.5 mL, and AIL=1.57 
cm2.  (A full description of the absorption module can be found in Chapter 2). 
 
3.3.5 AGS Tuning and Validation 
With the value of P in hand, the AGS was tuned to absorb KTZ with a physiologically 
relevant rate constant, ka=0.013 min
-1.107 To do so, Eq. (3.2) was used to select the 
intraluminal fluid flow rate (Q) and hollow fiber number (N) to obtain a ka,AGS 




Then, a mass transport study from an initially saturated solution of KTZ in pH 6.5 
phosphate buffer donor was conducted at 37℃ into the same drug-free buffer that was 
pumped into the tuned AGS. A validating estimate of ka,AGS was obtained by fitting the 
extraluminal concentration-time profile to Eq. (3.1) and comparing it to the “target” value, 
ka. 
3.3.6 Study of Simultaneous Desupersaturation and Absorption from KTZ Supersaturated 
Solutions using the Tuned AGS 
KTZ mass transport studies from supersaturated solutions in the donor were conducted 
using the tuned AGS to simulate absorption at a biorelevant rate. The pH-shift method was 
used to generate supersaturated solutions of three concentrations, 20, 100 and 140 µg/mL, 
the former being below and the latter two being above the amorphous solubility 
concentration of KTZ. Briefly, KTZ was dissolved in pH 1.5 HCl at concentrations 0.75, 
3.79 and 5.25 mg/mL. Then, 66 μL of each of the acidic stock solutions was added to 2.434 
mL of pH 6.5 phosphate buffer in a 3 mL UV-Vis spectrophotometer cuvette, which we 
call the donor cuvette. Intraluminal fluid flow was initiated, and the absorption module was 
inserted into the donor cuvette immediately upon generation of the supersaturated solution. 
KTZ concentrations in the donor and flow-through cell were monitored at 37℃ for 60 
minutes. Wavelength scans from 340 nm to 200 nm at the rate of 465 nm/minute were 
started within a minute of supersaturation generation and were conducted every 30 seconds, 
alternating between the drug donor and flow-through cells. Intraluminal drug 
concentrations were determined from the UV absorbance profiles at 225 nm and donor 
diffusible drug concentrations were determined by second derivative spectroscopy (to 




evolution of the dispersed phase, extinction-time profiles of KTZ solution in the donor at 
a non-absorbing wavelength of 312 nm were also recorded for all runs.  
To demonstrate the changes in KTZ donor solution phase behavior when the drug is 
removed at rates lower than the biorelevant (i.e. physiological) rate, the intraluminal fluid 
was run at two sub-biorelevant flow rates, while otherwise maintaining the same 
experimental conditions as those used above in the studies with the optimized, biorelevant 
AGS. Additionally, ‘closed no-absorption’ experiments were conducted by suspending 
hollow fibers devoid of intraluminal buffer in the drug donor. All measurements were 
carried out in duplicate.  
Using the quasi-steady state model for absorption in the AGS (developed in Chapter 
2), the intraluminal drug concentration exiting the hollow fiber module, 𝐶𝐼𝐿(𝐿, 𝑡), is given 
by 




The cumulative amount, 𝐴𝑀𝑇(𝑡), of KTZ absorbed by the intraluminal fluid at time t=60 
min was calculated by multiplying the area under the intraluminal concentration-time 
curve, 𝐴𝑈𝐶IL,0−t , by the corresponding flow rate, i.e. 








3.4.1 KTZ solubility measurements 
The crystalline solubility of KTZ in pH 6.5 phosphate buffer at 37℃ was found to be 
5.5 ± 0.3 µg/mL. To determine the critical concentration at which LLPS occurred, UV 
extinction at a non-absorbing wavelength of 312 nm was monitored as a function of KTZ 
concentration added to the cuvette. It is clear from the UV extinction data in Figure 3.2 
(black circles) that turbidity (indicating the presence of a dispersed phase) was negligible 
at low drug concentrations, slightly increased at 70 µg/mL before rising abruptly at 80 
μg/mL, the LLPS onset or amorphous solubility concentration of KTZ. The slight increase 
at 70 µg/mL may be attributed to crystalline precipitation which can also cause an increase 
in extinction. Induction of crystalline precipitation occurs at lower concentration of around 
45 µg/mL (grey squares in Figure 3.2) when the rate of addition of KTZ concentrated stock 
solution to pH 6.5 phosphate buffer was reduced from 10 to 3 µL/min due to 
supersaturation existence for longer time duration. KTZ added to the supersaturated 
solution above amorphous solubility was immediately added to the amorphous drug-rich 















Figure 3.2. Determination of KTZ LLPS onset concentration in pH 6.5 phosphate buffer 
at 37℃ using UV spectroscopy. Concentration of drug added corresponding to the point 
of abrupt increase in UV-extinction is 80 µg/mL, the amorphous solubility concentration 
of KTZ. 
 
3.4.2 Characterization of the KTZ Dispersed Phase 
KTZ is regarded as a slow crystallizer.106 At a concentration of 100 μg/mL, the solution 
is visually cloudy. Examination of this system under cross polarized light revealed the 
growth of small, non-birefringent, spherical droplets dispersed in the aqueous continuous 
phase (Figure 3.3a, at 5 and 18 minutes), suggesting that LLPS had occurred above the 
‘miscibility’ concentration of KTZ resulting in the formation of an amorphous, drug-rich 
phase.102 When observed for about an hour, this metastable solution, in the next stage 
starting at around 11 min, is characterized by crystal nucleation and growth with the 
disappearance of surrounding droplets (Figure 3.3a at 18 and 45 minutes). The zone of 
depletion grows with time, indicating solution mediated phase transfer from the amorphous 
liquid phase into the solid crystalline phase.110  On the other hand, observation of a 20 




indicated the presence of only birefringent crystals (Figure 3.3b). At 20 µg/mL, KTZ 
solution is below the LLPS onset concentration, but it is still supersaturated with respect to 
the crystalline drug. As a result, this metastable solution undergoes precipitation, but only 













Figure 3.3. Polarized light micrographs showing (a) evolution of a 100 µg/mL (above 
amorphous solubility) KTZ supersaturated solution over 45 minutes as it first undergoes 
LLPS to form non-birefringent amorphous droplets dispersed in a continuous pH 6.5 
phosphate buffer medium. The growth of droplets is then followed by birefringent crystal 
formation and simultaneous depletion of surrounding droplets. (b) Formation of only 
birefringent KTZ crystals at the end of 45 minutes in a 20 µg/mL (below amorphous 
















Figure 3.4. Donor drug concentration-time plots at three different starting drug 
concentrations of KTZ. The experimental data sets were fit to Eqs. (3.1) and (3.2) (black 
lines) to obtain 𝑃 = ( 6.74 ± 0.35 ) ×  10−5 cm/sec. 
 
KTZ mass transfer experiments across the hollow fiber membrane were conducted 
using concentrations at sub-solubility levels in pH 6.5 phosphate buffer at 37 ℃. The AGS 
was operated at an intraluminal fluid flow rate Q=160 µL/min, total hollow fiber area for 
absorption NAIL=7.85 cm
2 and donor volume of V=2.5 mL. Figure 3.4 shows the donor 
(extraluminal) concentration-time profiles of KTZ obtained from continuous UV 
spectrophotometric measurements. The decline in donor drug concentration due to 
absorption across the hollow fibers was exponential and after 120 minutes, about 70% of 
the drug was cleared from the KTZ donor solution. The permeability coefficient, 𝑃, was 
estimated by fitting the respective donor concentration-time series obtained to Eq. (3.1) 
and then using Eq. (3.2). From these curves, 𝑃 of KTZ across the mPES hollow fiber 
membrane was estimated to be (6.74 ± 0.35) ×  10−5 cm/s.  

























































Figure 3.5. (a) Family of plots of 𝑘𝑎,𝐴𝐺𝑆 of KTZ as a function of hollow fiber surface area 
for absorption (𝑁𝐴𝐼𝐿, 1.57 - 12.56 cm
2) and receiver fluid flow rate (𝑄, 0 – 2 mL/min) 
obtained using Eq. (3.2). AGS operating parameters were optimized to obtain a target 
𝑘𝑎,𝐴𝐺𝑆 of 0.013 min
-1. Volume of extraluminal fluid, V, was maintained at 2.5 mL.                 
(b) Donor concentration-time plot of KTZ at a starting concentration of 5.5 µg/mL obtained 
using the optimized AGS. Red line represents the fit of Eq. (3.1) to the experimental data 







The physiological absorption rate constant of KTZ is 𝑘a= 0.013 min
-1.107 Upon setting 
the intraluminal fluid flow rate at Q=160 µL/min and the number of hollow fibers at N=6, 
this rate constant (𝑘a,AGS) is attained (red star in Figure 3.5a). Figure 3.5b displays a run 
of the AGS with these parameters, starting with a saturated solution of KTZ in the donor. 
The parameter 𝑘a,AGS was estimated by fitting the experimental concentration-time profile 
to Eq. (3.1) (red line in Figure 3.5b) and was found to be 0.01261 ± 0.00076 min-1 which 
is close to the physiological 𝑘a for KTZ. 
3.4.5 Simultaneous Desupersaturation and Absorption from KTZ Supersaturated Solutions 
using the Tuned AGS  
3.4.5.1 ‘Closed’ versus ‘Open’ SSF Testing Systems 
 







Figure 3.6. Apparent KTZ concentration (solid line)- and extinction (dashed line)-time 
profiles obtained with ‘Control’ (no absorption module, red line) and ‘Test’ (tuned AGS, 
black line) at three different supersaturating concentrations of (a) 20 µg/mL, (b) 100 µg/mL 




The time evolution of phases in KTZ supersaturated solutions generated by the pH-
shift method in the donor cuvette below (20 µg/mL) and above (100 and 140 µg/mL) the 
LLPS onset concentration (80 µg/mL) was monitored with and without the 
“physiologically” tuned absorption module. Henceforth, systems with the tuned AGS will 
be referred to as ‘test’ while ‘control’ refers to those that are ‘closed’ (no flow in the 
absorption module) with respect to the drug in solution. Phase evolution was studied by 
continuously monitoring light scattering (UV extinction) and diffusible drug concentration 
(second derivative UV absorbance) in pH 6.5 phosphate buffer donor media for 60 minutes 
at 37℃ (Figure 3.6).   
Since KTZ supersaturated solution is metastable with respect to the stable crystalline 
form, precipitation by crystallization can occur (Figure 3.3b). Figure 3.6a shows the mean 
extinction- and concentration-time profiles from one hour ‘control’ and ‘test’ runs starting 
at 20 µg/mL KTZ extraluminal concentration. In the ‘control’, where no absorption occurs, 
reduction in drug concentration is solely due to crystallization (solid red line). The decline 
in drug concentration in the ‘control’ was also accompanied by a nonlinear increase in 
extinction (dashed red line) due to light scattering as nucleation and growth of a stable 
crystalline form proceed in the cuvette. Relative to the control, the rate and extent of 
increase in light scattering in the ‘test’ solution is much less (dashed black line), as 
absorption into the lumen reduces drug concentration in the donor, which in turn decreases 
the driving force for crystallization. Tuning of the AGS to attain an absorption rate constant 
of 0.013 min-1 translates to a 𝑡1/2 of 55 minutes. Thus, in the ‘test’ runs, the decline in drug 
concentration (solid black line) to about 50% of the starting concentration after 1 hr can be 




measurements made here, while eliminating the contribution due to light scattering by drug 
precipitate particles (amorphous and crystalline), does not necessarily eliminate their 
contribution to UV absorption, thereby somewhat overestimating extraluminal solution 
concentration.43,111,112 This allows only for qualitative and not quantitative analysis of the 
KTZ concentration evolution in donor. The wavelength where extinction was recorded, 
312 nm, can be considered non-absorbing in relation to both the molecularly dissolved drug 
as well as drug precipitate particles since we did not see a concentration-dependent change 
in second derivative intensity at that wavelength. The increase in intensity or extinction at 
312 nm can then be solely attributed to light scattering by the growing drug precipitate in 
the extraluminal solution. 
Figure 3.6b shows the apparent concentration- and extinction-time profiles of ‘control’ 
and ‘test’ samples at 100 µg/mL starting drug concentration in the donor. Although 100 
µg/mL KTZ was added, only about 80 µg/mL KTZ was measured in ‘test’ and ‘control’ 
solutions at the start of the run. This is the limit of miscibility or amorphous solubility of 
KTZ, and the additional 20 µg/mL forms the dispersed phase. Concentration remains 
relatively constant for the first 7 and 15 minutes in the ‘control’ and ‘test’ runs, 
respectively, and then declines. The subsequent decline of drug concentration in the 
‘control’ can be attributed to drug crystallization. Moreover, the extinction of the ‘control’ 
samples increases slowly at first, accelerates, and slows down again, presumably due to the 
appearance and growth of amorphous droplets followed by crystal nucleation and growth 
with simultaneous dissolution of the amorphous phase. This solution phase behavior was 
also observed when 100 µg/mL supersaturated solution was observed under cross-




closely with the duration of constant drug concentration in solution, indicating a relatively 
stable amorphous precipitate. In the ‘test’, the decline in drug concentration is due to both 
absorption and crystallization. Extinction on the other hand remains constant at first, 
indicating the formation of an amorphous dispersed phase, and then decreases within 15 
minutes, which corresponds to the duration of constant drug concentration. This is probably 
due to rapid dissolution of amorphous droplets to replenish the drug in solution lost to 
absorption, which serves to maintain a constant solution concentration but depletes the 
dispersed phase of KTZ, resulting in declining extinction. This is followed by 
crystallization indicated by a steady increase in extinction, although the rate and extent are 
significantly lower compared to the ‘control’.  
As the concentration of drug added to solution increases, crystallization becomes 
highly favorable as the frequency of molecular collisions and stable nuclei formation 
increases. This is seen in the concentration- and extinction-time profiles of both ‘control’ 
and ‘test’ in Figure 3.6c when 140 µg/mL KTZ was added to pH 6.5 phosphate buffer, 
compared to the 100 µg/mL case. In the ‘control,’ following an initial high extinction due 
to larger and/or greater number of KTZ amorphous liquid droplets dispersed in the aqueous 
continuous phase, extinction decreases sharply as a result of rapid amorphous droplet 
dissolution to undergo solution-mediated phase transfer to the solid crystalline phase, 
which in turn causes a slight increase in light scattering and extinction. The concentration 
of KTZ, on the other hand, remains relatively constant in the first few minutes at 80 µg/mL 
and then rapidly decreases to its equilibrium solubility concentration due to crystallization. 
The ‘test’ extinction- and concentration-time profiles follow a similar trend but with longer 




of increase in extinction, indicating a lower degree of crystallization in the presence of the 
absorptive sink.  
 
3.4.5.2 Significance of Simulating Absorption at a Biorelevant Rate 
There is often a discrepancy between the in vitro prediction of the nature and extent of 
intestinal precipitation of a BCS-II weak base and the real outcome in vivo.76,84,98,103,104 
This discrepancy arises because many in vitro methods do not consider the effect of drug 
removal from the intestinal lumen by absorption at a biorelevant rate, especially for a high 
permeability drug. Plasma concentration-time profiles from a clinical trial of KTZ oral 
solution showed a fast absorption phase with a t1/2 of about an hour.
113 Such rapid 
absorption can potentially reduce the driving force for crystallization. So, to test the 
hypothesis that precipitation may be overestimated when a sub-optimal gut simulator is 
used, lower-than-biorelevant absorption rates were also simulated by the AGS. 
Of the various parameters that are available to the designer/operator of the AGS, the 
easiest to vary is the intraluminal fluid flow rate. In the following studies, 20, 100 and 140 
µg/mL supersaturated solutions were generated by the pH-shift method in the donor, and 
the absorption module was operated at two sub-biorelevant intraluminal fluid flow rates, 
40 and 80 µL/min.  
Mean extraluminal and intraluminal concentration-time profiles obtained using the 
sub-biorelevant AGS are compared with those obtained using the biorelevantly tuned AGS 
(Q=160 µL/min) in Figure 3.7. If there were no precipitation, these profiles would be 
predicted using Eqs. (3.1), (3.2), and (3.3). The predictions so obtained are represented by 




experimental data sets (lines). Negative deviation from the predictions of intraluminal drug 
concentration absorbed determined experimentally should be indicative of relative non-
availability of drug in the donor for absorption due to formation of drug aggregates and 
crystals (compared to free drug species), the hydrodynamic radii of which are larger than 
the pore size of the hollow fiber membrane (~ 2 nm, from manufacturer data sheet).  
We first consider results for 20 µg/mL starting concentration of KTZ (Figure 3.7a,b).  
Notably, Figure 3.7a displays no obvious relation between intraluminal flow rate (if any) 
and the decay in extraluminal concentration. With increasing flow rate, absorption is faster, 
and the crystallization rate decreases, since the concentration of drug, and hence the driving 
force for crystal nucleation and growth, is lessened. The combination of these two trends 
makes it difficult to decouple them by looking at donor concentration alone. With 
increasing flow rate, as the residence time of the buffer in the hollow fiber lumen decreases, 
concentration of drug absorbed per unit volume of the intraluminal fluid decreases (Figure 
3.7b). However, the cumulative dose fraction of free drug diffused into the intraluminal 
buffer medium from the donor after 60 min [AMT(60 min) as calculated using Eq. (3.4) 
normalized by dose], increases with increasing flow rate (Figure 3.8). The initial slow 
absorption can be attributed to the diffusional time-lag of KTZ across the hollow fiber 
membrane and the residence time of the buffer in the hollow fiber lumen, which increase 
with decreasing flow rate. The quasi-steady state model (developed in Chapter 2) did not 
take into account this delay, which explains the initial deviation of the predictions from the 
experimental data in all cases. Nevertheless, the predictions show larger deviations from 




the 160 µL/min case. These observations indicate increasing extent of crystallization with 
slower absorption. 
When 100 µg/mL KTZ supersaturated solution was prepared, the maximum 
concentration in the donor attained in all the systems was 80 µg/mL, the amorphous 
solubility of KTZ (Figure 3.7c). In the absence of crystallization, per earlier investigations, 
as the degree of supersaturation increases, the chemical potential and flux of drug across a 
membrane also increases, attaining a maximum at its amorphous solubility concentration.55 
Beyond the maximum miscibility concentration, the chemical potential and flux are 
constant. The predictions made here assumed maximum flux at 80 µg/mL, which remained 
constant even at higher dose concentrations. In the absence of crystallization, the predicted 
donor concentration-time profile indicates that the amorphous drug rich nanodroplets in 
dynamic equilibrium with the drug in solution immediately replenish the drug in solution 
lost to absorption, thereby maintaining the initial constant drug concentration (as 
determined by second derivative UV spectroscopy) in the donor. Once the amorphous 
phase is exhausted, the drug concentration decreases as does flux across the membrane. 
The 160 µL/min experimental dataset is in good agreement with the theoretical model, 
indicating the occurrence of drug-rich phase redissolution followed by a decline in drug 
concentration, both due to absorption and some crystallization (Figure 6c,d). At lower rates 
of absorption, however, decline in drug concentration begins earlier than predicted, 
indicating significant crystallization. Crystallization in the donor reduces the drug available 
for absorption, resulting in lower than predicted KTZ concentration absorbed by the 
intraluminal buffer at lower flow rates. Moreover, as the dose concentration increased from 




optimal AGS also increased due to higher KTZ free drug concentration and activity in 
solution, which increased its driving force for absorption (Figure 3.8). Similar to the 20 
µg/mL case, highest KTZ dose fraction was absorbed after 60 minutes with the 
physiologically tuned AGS and decreased when sub-optimal intraluminal fluid flow rates 
were used.  
At 140 µg/mL dose concentration in the donor, significant crystallization, subsequent 
decline in donor drug concentration, and deviation from the model prediction occur in all 
cases (Figure 3.7e). The rate of decline is the lowest in the 160 µL/min case, followed by 
80 µL/min, then 40 µL/min and the ‘control’ cases. From Figure 3.7f it is clear that the 
predicted intraluminal concentration-time profiles show significant deviation from the 
experimental data in all the cases. At 140 µg/mL dose concentration, irrespective of the 
flow rate, a lower fraction of drug is absorbed relative to a lower dose concentration of 100 
µg/mL due to extensive crystallization (Figure 3.8).  
It is interesting to note that at all dose concentrations, the fraction of KTZ absorbed is 
lower than 0.5, approximately the fraction of drug absorbed from a saturated solution in 60 
minutes using optimized AGS (Figure 3.5b). This is due to crystallization in the donor 



































Figure 3.7. KTZ extraluminal concentration-time (a), (c) and (e) and intraluminal 
concentration absorbed with time (b), (d) and (f) profiles obtained with three different 
intraluminal buffer flow rates, 40, 80 and 160 (optimal) µL/min and ‘Control’ at three 
different initial concentrations of 20, 100 and 140 µg/mL, respectively. The predictions 
obtained using Eqs. (3.1), (3.2), and (3.3) if there were to be no crystallization are 






















Figure 3.8. KTZ dose fraction absorbed [dose-normalized AMT(60min) determined using 
Eq. (3.4)] in ‘tests’ with sub-optimal and optimal AGS at three supersaturating 




There is a well-documented need in the literature, especially in reference to KTZ, to 
not only include an absorptive sink during in vitro dissolution testing, but also be able to 
characterize precipitation behavior upon supersaturation generation.98,103,104 If KTZ 
supersaturated solution precipitates to its metastable amorphous phase, the solution will 
still be supersaturated with respect to the stable crystalline form, thereby retaining the 
advantage of enhanced solute activity, and hence flux.55 Moreover, the amorphous form, 
in contrast to the crystalline form, can readily redissolve to replenish drug in solution lost 
to absorption. In vivo KTZ precipitate is described to be amorphous.77 However, 




reported in the literature, due either to utilization of non-sink dissolution testing or 
application of non-biorelevant flow rates of dissolution media in a flow through 
system.98,103,104  This drawback can be sufficiently addressed by a dissolution testing 
system that allows a biorelevant rate of drug clearance from the simulated intestinal lumen 
for a highly permeable BCS-II compound. 
KTZ is a BCS-II compound, supersaturated solutions of which can undergo LLPS 
above the amorphous solubility concentration of 80 µg/mL (Figure 3.2) followed by 
crystallization (Figure 3.3a). Below 80 µg/mL, crystallization is the only mechanism of 
concentration reduction of the diffusible drug species (Figure 3.3b). The hollow fiber 
based AGS introduced in Chapter 2 was tuned to absorb KTZ at a physiological rate 
(Figure 3.5a). Upon generation of supersaturated solutions of KTZ in the extraluminal 
fluid, crystallization was signaled by an increase in extinction (Figure 3.6). Although an 
increase in extinction was observed in both the ‘control’ solution as well as the ‘test’ with 
the tuned AGS, the rate and extent of light scattering was higher in the ‘control,’ indicating 
higher drug crystallization. This suggests that a traditional, closed USP dissolution testing 
tool would overpredict precipitation that occurs in the intestinal lumen, thereby 
underpredicting the performance of supersaturating formulations. 
Moreover, absorption from KTZ supersaturated solutions using the physiologically 
tuned AGS was compared with that obtained using the sub-biorelevant setup (Figure 3.7). 
Eqs. (3.1), (3.2) and (3.3) were used to predict the extra- and intraluminal concentration 
profiles sans crystallization. In the extraluminal fluid, at the lowest absorption rate, non-
exponential decline and largest deviation from the predicted profiles was observed, 




crystallization induction was significantly slower with the physiologically tuned AGS 
relative to the sub-biorelevant AGS and ‘control’. In the intraluminal fluid, on the other 
hand, lower-than-predicted concentration-time profiles were observed at all dose 
concentrations at lower flow rates.  
To quantify and compare the influence of crystallization on flux in all the cases, the 
excess in the predicted amount of KTZ absorbed relative to experimental, Δpredicted-experimental 
[experimental amount absorbed determined using Eq. (3.4), predicted amount absorbed 
determined using Eq. (3.3) and (3.4)] is plotted in Figure 3.9. Greater the difference, higher 
is the flux reduction due to crystallization. Overall, as the dose concentration increases, 
unsurprisingly, Δpredicted-experimental also increases. However, for all dose concentrations, as 
we increase the flow rate, Δpredicted-experimental decreases indicating lower crystallization in the 









Figure 3.9. Excess in the predicted amount of KTZ absorbed relative to experimental, 
Δpredicted-experimental plotted as a function of extraluminal dose concentrations and intraluminal 














































































The simplicity of the AGS system and the need to use only a small volume and mass 
of the dissolution media and drug formulation, respectively, allows its applicability to 
screen SSFs such as amorphous solid dispersions in a high-throughput manner, and study 
how additives such as polymers, surfactants or bile salts, added in either formulation or 
dissolution media, may influence the drug solute’s thermodynamic activity and ultimately 
its absorption. In fact, the importance of considering activity- rather than concentration-
based supersaturation in correctly predicting membrane transport rate has been 
demonstrated recently.14,114 Moreover, to further distinguish non-bioavailable ionized from 
bioavailable unionized species, the hollow fiber membranes, for example, may be coated 
with phospholipids, as the uncoated hollow fibers will indiscriminately absorb both, and 
can overestimate formulation efficacy, especially for drugs formulated as salts.115  A 
logical next step would also be to reduce the diffusional time-delay in absorption of drug 
into the intraluminal buffer by utilizing a much thinner HF membrane compared to that 














A simple and efficient in vitro dissolution/absorption testing tool, the AGS, was tuned 
to simulate absorption of a model BCS-II drug, KTZ, at its physiologically observed rate. 
The supersaturating solutions were evaluated at, below and above KTZ’s amorphous 
solubility concentration in the presence and absence of an absorptive sink. Direct evidence 
of crystallization was obtained by measuring extinction of donor solutions, the rate and 
extent of increase of which was found to be higher in the ‘closed’ system relative to the 
physiologically tuned AGS. Indirect evidence of crystallization was obtained by evaluating 
the cumulative amount absorbed by the intraluminal fluid as only free drug species will be 
available for absorption. Rate of absorption was found to be key in determining the degree 
of precipitation; Δpredicted-experimental increased as the absorption rate decreased indicating 
greater deviation from an exponential, first order decline of KTZ extraluminal 
concentration-time profile due to increasing precipitation which in turn decreases the 
absorptive flux across the hollow fiber membrane. This study illustrates the key role of 
including an absorption module during the dissolution testing of potential SSFs of high 
permeability drug molecules and simulating absorption with a physiologically observed 
















Chapter 4: Understanding the Impact of Absorption on In Vitro Dissolution, 



























Figure 4.1. Schematic representation of analytical techniques used to understand the 
exchange processes that occur in vitro upon amorphous solid dispersion (ASD) dissolution 
in the presence and absence of an absorptive sink. 
 
4.2 Introduction 
Amorphous solid dispersions (ASDs) are becoming increasingly relevant as oral drug 
formulations as more brick dust molecules enter the development pipeline.89,90 These are 
molecules whose solubility and dissolution rate in an aqueous medium are restricted by 
their high crystal lattice energy, low degree of molecular flexibility and high 
hydrophobicity.116 In an ASD, the amorphous form of the drug is molecularly dispersed in 




reduced hydrophobicity afforded by the polymer are responsible for solubility and 
dissolution rate enhancement of the drug.117  
Complex gastrointestinal exchange processes exist after ASD dissolution as the drug is 
distributed across free and various bound species (Figure 4.1).118 However, only free, 
molecularly dissolved drug is bioavailable.14,114,119 ASDs can release drug at 
concentrations above its crystalline solubility in a super-soluble or supersaturated state with 
higher thermodynamic activity which translates to increased drive for absorption.55 The 
enhanced solubility of the amorphous form over the crystalline solubility represents the 
drug’s miscibility limit in the media, also known as amorphous solubility.102 When the 
dose concentration of the drug exceeds its amorphous solubility, glass-liquid or liquid-
liquid (depending on the resultant species’ Tg) phase separation (LLPS) results in formation 
of a molecularly disordered colloidal amorphous precipitate dispersed in the dissolution 
media.90 The large surface area of the precipitate allows rapid redissolution of the drug to 
replenish the drug in solution lost to absorption.90 The drug in solution and/or amorphous 
precipitate can also revert to a low energy crystalline polymorph, the induction probability 
and crystallization rate of which increases with increasing drug concentration (as 
demonstrated with KTZ in Chapter 3). Polymer released from the ASD can stabilize this 
metastable, supersaturated solution against crystallization.120 
Apart from amorphous and crystalline precipitate, earlier reports have also indicated 
the formation of drug species bound to bile micelles and lipid nanoparticles of the 
dissolution media as well as polymer and surfactant excipients released from the drug 
formulation.14,119,121 Drug from these species can also disassociate to replenish free drug in 




constitute a gastric milieu that is very dynamic in nature due to continuous drug removal 
by absorption. In vitro assessment of ASD performance, on the other hand, is commonly 
performed under closed, non-sink conditions afforded by the standard United States 
Pharmacopeia (USP) dissolution testing apparatus which allows only static equilibria 
between various drug species. It has also been shown in an earlier study that a closed 
dissolution testing apparatus increases the crystallization propensity of supersaturated 
solutions (Chapter 3). This would prevent the assessment of full potential of ASDs or 
worse, may underestimate their efficacy.  
To simulate dynamic gastrointestinal equilibria, in vitro tools have been developed that 
allow continuous drug removal. The USP Apparatus 4 or the flow-through cell and the 
biphasic dissolution testing system, although employing different principles of operation, 
when optimized can mimic in vivo rates of drug removal from the intestinal lumen.105,122 
While the USP Apparatus 4 establishes sink conditions by maintaining a continuous flow 
of fresh dissolution medium to replace the drug-laden medium when operated in open-loop 
mode, the volumes employed are usually unphysiologically large.42 The biphasic 
dissolution testing system, on the other hand, lacks a membrane between the aqueous 
dissolution medium and the organic absorptive sink.123 Free drug species as well as drug 
nanoaggregates and complexes with media components and/or excipients can 
indiscriminately partition into the organic phase. Moreover, in vivo absorption is a kinetic 
process whereas partition coefficient of a drug is an equilibrium parameter that may not 
accurately represent physiological rate of drug removal from the intestinal lumen. Manual 
sampling (e.g. using microfilters) and analytical techniques (e.g. UV spectroscopy, HPLC) 




filter and detect only free drug species.43 These caveats in drug solution filtration and 
measurement may significantly overestimate the ability of an SSF to provide drug in a 
supersaturated, highly bioavailable form. 
Employment of membrane-based assay systems such as Parallel Artificial Membrane 
Permeability Assays (PAMPAs), the ultrathin, large-area membrane (UTLAM), side-by-
side, or MicroFLUX™ (µFLUX) and MacroFLUX™ diffusion cells, wherein the 
apical/donor and basal/receiver compartments are separated by a size-exclusion membrane 
barrier, has provided insights into how passive permeation of drug molecules may 
influence drug release, dissolution, precipitation and speciation.24,54–56,120,124–126 However, 
aside from the UTLAM system, these systems might be quite inflexible to scale-up to 
obtain physiologically relevant absorption rates. The major limitation of these systems is 
the small surface area for absorption relative to the volume for dissolution, resulting in 
lengthy, non-physiological experimental time scales (e.g. 16 hours with a side-by-side 
diffusion cell compared to 2-4 hours of gut transit time).58,59 
Using cell lines such as Caco-2 and MDCK instead of artificial membranes allows one 
to screen active and passive permeation mechanisms as well as efflux, if any.45,127,128  
However, these assays often suffer from high inter- and intra-lab variability, time 
consuming and expensive preparation steps, relative incompatibility with certain 
pharmaceutical excipients, and lower absorption surface area compared with the intestinal 
membrane.129,130  Moreover, considering that 80-95% of commercial compounds are 
absorbed primarily by passive diffusion, there is a great interest in rapid and inexpensive 




An inexpensive and rapid screening tool called the ‘Artificial Gut Simulator (AGS)’ 
introduced in Chapter 1 consisting of hollow fibers in the absorption module can be used 
to screen ASDs. The hollow fiber module is suspended in a UV spectrophotometric ‘donor’ 
cuvette while a ‘receiver fluid’ buffer is pumped continuously through a flow-through cell 
following the hollow fiber lumen to allow continuous, in-line measurement of donor and 
receiver (intraluminal) drug concentrations. The low membrane molecular weight cutoff 
(MWCO) of the hollow fiber membrane allows permeation of mostly free drug species into 
the receiver media, while the non-bioavailable species in aggregates and precipitate remain 
unabsorbed. Operating parameters of the AGS such as the surface area of hollow fibers, 
receiver fluid flow rate and volume of donor medium are directly controlled by the 
designer/operator and can be tuned to mimic the known in vivo absorption rate constant of 
a drug under study, when that drug is present at or below saturation in the gut. 
In this study, ASDs of ketoconazole (KTZ) are formulated with hypromellose acetate 
succinate (HPMCAS) polymer, which is known to interact favorably with KTZ.131 The 
goal of the present study is to introduce an analytical paradigm to systematically elucidate 
the impact of various drug species formed during ASD dissolution on absorption across 
the AGS hollow fiber membrane. A concurrent study with a non-sink dissolution-only 
‘control’ is also conducted to understand the impact of absorption on drug dissolution and 







4.3 Materials and Methods 
4.3.1 Materials 
KTZ drug (Laborate Pharmaceuticals, Haryana, India) and HPMCAS polymer (HF 
grade, Ashland Global Specialty Chemicals Inc., DE) were pre-dried overnight at 80℃ to 
remove residual moisture before use. Hydrochloric acid (36.5-38.0%), methanol, 
concentrated sulfuric acid, benzene and phenol were purchased from Sigma-Aldrich Co., 
MO and were used as received.  
Fasted-state simulated intestinal fluid is typically prepared by dissolving FaSSIF-V2 
powder (Biorelevant.com Ltd., London, UK) containing bile salts and lecithin at a quantity 
prescribed by the manufacturer into pH 6.5 maleate buffer. However, maleic acid in 
biorelevant media can result in difficulties during low wavelength UV quantification of 
drug substances such as KTZ whose wavelength of maximum absorbance is 225 nm.38,132 
This is not a problem with phosphate buffer due to lack of observable UV absorbance of 
phosphate ion around the wavelength of interest. 38,132 Therefore, in this study, 31.8 mM 
phosphate buffer of matching pH, osmolality and buffer capacity as maleate buffer was 
prepared using monobasic sodium phosphate monohydrate, dibasic sodium phosphate 
heptahydrate and sodium chloride purchased from Sigma-Aldrich Co. (Table 4.1).38,132,133 
The measured crystalline and amorphous solubilities of KTZ were the same in both the 
media. The modified FaSSIF-V2 media was used as a drug ‘donor’ media in this study. pH 
6.5 phosphate buffer, without the bile salts and lecithin used for modified FaSSIF-V2 
preparation, was used as a ‘receiver’ media pumped continuously through the intraluminal 
















The AGS was constructed as outlined in Chapters 2 and 3 with slight modification. 
Briefly, hollow fibers supported on a laser-cut plexiglass support framework were potted 
into inlet and outlet tubes for intraluminal/receiver media emerging from cuvette cap  
(Azzota Scientific, DE) using a silicone UV-cure glue (Henkel Corporation, OH). In this 
study, however, modified polyether sulfone (mPES) hollow fibers were replaced with 13 
kDa MWCO regenerated cellulose-based hollow fibers (Spectra/Por® In Vivo 
Microdialysis Hollow Fibers, Repligen Corporation, CA) of d=200 µm and L=5 cm. The 
cellulose hollow fibers had more neutral surface preventing drug adsorption to the 
membrane and much thinner walls (40 µm, compared to 125 µm of mPES hollow fiber) 







4.3.2 Crystalline and Amorphous Solubility Determination of KTZ in FaSSIF-V2 media 
Crystalline and amorphous solubilities of KTZ were determined in pH 6.5 FaSSIF-V2 
media without and with pre-dissolved HPMCAS polymer at concentrations ranging from 
0.5 to 4.0 mg/mL at 37℃. Solubility determinations were made using the method described 
earlier.102 Briefly, for amorphous solubility measurement, concentrated KTZ stock solution 
(6 mg/mL) in pH 1.5 HCl was titrated into 3 mL FaSSIF-V2 media contained in a quartz 
cuvette at a rate of 10 µL/min under constant stirring. Light scattering or extinction was 
measured by UV spectroscopy (Cary 100 Bio, Agilent Technologies, Inc., CA, path length 
10 mm) at a non-absorbing wavelength of 340 nm. An abrupt increase in extinction 
indicated the appearance of LLPS and the corresponding concentration was taken to be the 
amorphous solubility concentration. Crystalline solubility was determined by equilibrating 
excess solid KTZ in FaSSIF-V2 media for 48 hours followed by separation of undissolved 
solids by centrifugation (Marathon 26KMR microcentrifuge, Thermo Fisher Scientific 
Inc., MA) and determination of drug concentration in the supernatant.  
Additionally, the effect of increasing HPMCAS concentration in FaSSIF-V2 media on 
concentration, size and zeta potential of amorphous nanodroplets was evaluated using 
nanoparticle tracking analysis (NTA, NanoSight LM-10, Malvern Instruments, MA) and a 
zeta potential analyzer (Stabino, Particle Metrix GmbH, Inning am Ammersee, Germany), 
respectively. Briefly, KTZ at a concentration of 290 µg/mL (above its amorphous 
solubility) was introduced in media containing 0 – 1.5 mg/mL pre-dissolved HPMCAS. A 
400 nm laser light source was directed towards KTZ nanodroplets dispersed in the media 
which filled an NTA sample cell mounted on the stage of a microscope. These particles 




larger ones, scattered a small amount of light out through an optical window where it was 
collected by a 20x magnification microscope objective. NanoSight software determined 
the diffusion coefficient of the particles based on the recorded particle Brownian motion, 
and then the hydrodynamic diameter using the Stokes-Einstein relation.  
4.3.3 Preparation of ASDs by Rotary Evaporation 
KTZ and HPMCAS polymer ASDs were prepared at 1:9, 2:8 and 3:7 weight ratios. An 
appropriate quantity of drug and polymer powders was dissolved in methanol by heating 
at 50℃ for 20 minutes in a water bath. Solvent was removed using a rotary evaporator 
(IKA-HB10 digital system rotary evaporator, Werke. GmbH and Co., Staufen, Germany) 
at 50℃ under reduced pressure (25 mm of Hg). The solid dispersions were further dried at 
room temperature for 24 hours in a vacuum desiccator. The dried ASDs were cryomilled 
(Model 6750 Freeze Mill, Spex SamplePrep, NJ) in a cylindrical polycarbonate vial (SPEX 
SamplePrep #6751 vials) equipped with a stainless-steel impactor and submerged in liquid 
nitrogen throughout the milling process. Not more than 1 g of the sample was loaded at a 
time, pre-cooled in liquid nitrogen for 10 minutes following which the samples were milled 
for 30 seconds at a constant milling rate of “10” (i.e. 20 impacts/second) per cycle and five 
such cycles were performed. Samples were then equilibrated to room temperature in a 
desiccator and then stored at −20℃ until further use.  
Differential Scanning Calorimetry (DSC) was performed to confirm the amorphous 
nature of the prepared dispersions. Briefly, a differential scanning calorimeter (TA 
instruments Q2000, Delaware, USA) equipped with a refrigerated cooling unit was used. 
The instrument was calibrated with indium. To make measurements, 1-4 mg of sample was 




nitrogen purge (50 mL/min). The melting point and glass transition temperature were 
determined by heating the sample at a rate of 10℃/min to 100℃, rapidly cooling to 0℃  
followed by reheating at a rate of 10℃/min to 200℃. DSC data was analyzed using 
Universal Analysis software.  
4.3.4 Simultaneous Dissolution and Absorption Testing Study with AGS 
The AGS, consisting of a cellulose hollow fiber-based absorption module suspended in a 
‘donor’ UV spectrophotometric quartz cuvette, was used to assess the performance of 
ASDs. First, the operating parameters were tuned to absorb KTZ at a physiological rate 
constant, 𝑘a = 0.013 min
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was matched to the target 𝑘a by selecting N, number of hollow fibers and Q, the hollow 
fiber intraluminal fluid flow rate (Chapters 2 and 3). Donor volume, V and lateral surface 
area of each hollow fiber, 𝐴IL were set at 1.8 mL and 0.32 cm
2, respectively. The 
permeability coefficient of KTZ, P, across the cellulose hollow fiber membrane was 
determined to be (1.05 ± 0.07) x 10-4 cm/s using a method described earlier (Chapters 2 
and 3). To verify that the AGS was tuned to absorb at 𝑘a,AGS, a mass transport study was 
conducted at 37℃ from an initially saturated solution of KTZ in FaSSIF-V2 media into 
intraluminal phosphate buffer pumped at the selected flow rate using a syringe pump. An 
estimate of 𝑘a,AGS was obtained by fitting the extraluminal concentration-time profile 






The tuned AGS was then used to conduct mass transport studies from supersaturated 
solution of KTZ generated in the donor upon ASD dissolution at 37℃. The three ASDs – 
1:9, 2:8 and 3:7 KTZ:HPMCAS – were weighed into a home-made dissolution sample 
holder (with an attached magnetic stir bar that also functioned as a sinker) to dose KTZ at 
90, 120, 180, 240, 300 and 400 µg per mL of FaSSIF-V2 media in the donor. Hollow fiber 
intraluminal fluid flow was initiated, and the absorption module was inserted into the donor 
cuvette immediately upon the introduction of sample holder containing the ASD powder. 
Multi-cell UV spectrophotometer equipped with magnetic stirring was used to conduct 
wavelength scans from 340 to 200 nm every minute for 120 min at the rate of 465 nm/min, 
alternating between drug donor cuvette and a flow through cell to measure KTZ 
concentration in the intraluminal fluid exiting the absorption module. The intraluminally 
absorbed KTZ concentration was determined from UV absorbance profiles at 225 nm and 
donor concentrations were determined by second derivative spectroscopy, also at 225 nm. 
Additionally, a non-sink dissolution study was conducted as a ‘control’ by suspending 
hollow fibers devoid of any intraluminal fluid into the drug donor cuvette. All 
measurements were carried out in duplicate.  
4.3.5 Effect of KTZ solution-state activity on absorption 
The amount of KTZ absorbed is directly related to its activity in solution or, in other 
words, the concentration of ‘free’ drug available for diffusion across the hollow fiber 
membrane.22 To evaluate the effect of polymer on KTZ solution-state activity, KTZ 
absorption from saturated drug solutions prepared in FaSSIF-V2 media containing 0-4 
mg/mL pre-dissolved HPMCAS polymer was determined. Initially saturated solutions 




donor. The concentration of drug absorbed by the intraluminal fluid was below the limit of 
quantification and could not be reliably measured. The donor drug concentration was 
measured by UV spectroscopy every minute for 60 min and the amount depleted from the 
donor was taken to be the amount absorbed. To evaluate reduction in the fraction of free 
drug with increasing concentration of polymer dissolved, KTZ fraction depleted in the 
donor with pre-dissolved polymer was normalized by the fraction depleted in the absence 
of polymer.  
4.3.6 Effect of absorption on drug and polymer release kinetics 
The effect of absorption on KTZ and HPMCAS release kinetics was evaluated by 
measuring their concentration released into both the non-sink ‘control’ and AGS donor 
media from 1:9, 2:8 and 3:7 KTZ:HPMCAS ASDs. Only one dose concentration of KTZ, 
90 µg/mL, was evaluated since minimal precipitation can be expected in this case. Briefly, 
non-sink ‘control’ and mass transportation runs with the tuned AGS were conducted for 5, 
15, 30, 45 and 60 minutes. At the end of each time point, the non-sink ‘control’ and AGS 
donor media in entirety was subjected to centrifugation at 14,800 rpm (Marathon 26KMR 
microcentrifuge, Thermo Fischer Scientific Inc., MA) for 10 minutes followed by filtration 
of the resultant supernatant through a pre-saturated 0.2 micron nylon filter (VWR 
Technology, PA) to get rid of undissolved drug and precipitate, if any. The concentration 
of KTZ in the filtered supernatant were measured by UV spectroscopy at 225 nm. The 
concentration of HPMCAS was determined using a colorimetric method by DuBois et al.136 
10 µL of the filtered supernatant was diluted to 1 mL with distilled water and was treated 
with 25 µL of 80% w/w phenol solution and 2.5 mL concentrated sulfuric acid. The 




conjugated complex and the polymer concentration was determined by visible 
spectroscopy at 490 nm. The calibration curve for polymer concentration was prepared 
with reference solutions containing 0.01 to 4 mg/mL HPMCAS polymer.  
In case of the mass transport study with AGS, the concentration of drug absorbed by 
the receiver fluid was also simultaneously measured every minute, also by UV 
spectroscopy at 225 nm. All measurements were made in duplicate and expressed as 
percentage of drug or polymer released calculated as per Eqs. (4.3) – (4.6). 
% polymer released =
Conc. of polymer measured in the dissolution media ×  𝑉𝐸𝐿 × 100
Total polymer amount in ASD
(4.3) 
% drug released in ′control′ =
Conc. of drug measured in the dissolution media ×  𝑉𝐸𝐿 × 100
Total drug amount in ASD
(4.4) 
where 
% drug released in AGS donor =
[(Conc. of drug measured in the dissolution media × 𝑉𝐸𝐿) + Cumulative KTZ amount absorbed] × 100
Total drug amount in ASD
(4.5)
 
Cumulative KTZ amount absorbed(t) =  AUC𝐼𝐿,0−𝑡 × 𝑄 (4.6) 
and AUC𝐼𝐿,0−𝑡 is the area under the receiver concentration-time curve and in this experiment, 
t = 60 min. 
4.3.7 Effect of absorption on crystalline and amorphous precipitation  
Mass balance was used to quantitate precipitation in both the non-sink ‘control’ and 
the AGS donor at the end of 120 minutes of dissolution and mass transport runs conducted 
above (Section 4.3.4).   
Non-sink ‘control’: 
Total precipitate (fraction of dose) =








Total precipitate (fraction of dose) =







Amount of drug absorbed at the end of 120 minutes from the AGS donor can be 
determined from the AUC of receiver concentration-time profiles using Eq (4.6) at t=120 
min.  
Concentration of drug remaining in the donor at 120 minutes may not be reliably 
determined by direct UV absorbance measurement since the precipitate particles may also 
absorb UV radiation, thereby overestimating drug concentration.43 KTZ ‘control’ and AGS 
donor solutions were collected at the end of 120 min and subjected to ultracentrifugation 
at 35,000 rpm for 15 minutes in an Optima L-100 XP ultracentrifuge with swinging-bucket 
rotor SW 41 Ti (Beckman Coulter Inc., CA). KTZ concentration in the supernatant devoid 
of precipitate was determined by UV spectroscopy at 225 nm. Using these estimates of 
drug concentration remaining in the dissolution media, total precipitate fractions were 
calculated using Eqs. (4.7) and (4.8).  
Total precipitate consists of both amorphous and crystalline drug species. Fluorescent 
probes have been utilized elsewhere to detect LLPS and quantify amorphous precipitate in 
supersaturated drug solutions as they exhibit a large hypsochromic shift and increase in 
peak intensity with decreasing environmental polarity upon LLPS.22,42 In the present case, 




Fourteen reference solutions of KTZ (concentration ranging from 25 to 616 µg/mL) 
were prepared in FaSSIF-V2 media by the pH-shift method (described in detail in Chapter 
3). Fluorescence emission spectra from 341 to 450 nm were recorded using a Cary Eclipse 
fluorescence spectrometer (Agilent, CA) at an excitation wavelength of 340 nm, with a 
sampling interval of 1 nm, scan rate of 600 nm/min and excitation and emission slit width 
of 5 nm. Below the amorphous solubility concentration, KTZ showed emission maxima at 
380 nm which reduced to 353 nm upon LLPS above amorphous solubility (Appendix, 
Figure A4a,b). This is similar to hypsochromic shift seen in KTZ emission spectra as the 
media in which KTZ is dissolved is changed from relatively polar ethanol to non-polar 
benzene (Appendix, Figure A4c,d). LLPS is also marked by an abrupt increase in intensity 
at the amorphous solubility concentration (Appendix, Figure A4b). To develop a 
calibration curve for the determination of KTZ amorphous precipitate amount in 
dissolution media at the end of 120 minutes of dissolution and mass transport runs, 
fluorescence emission intensity at 353 nm of reference solutions above amorphous 
solubility concentration was plotted as a function of amount of amorphous precipitate 
present in solution calculated by mass balance Eq. (4.9).  
Amount of amorphous precipitate per mL = Total KTZ concentration − Amorphous solubility (4.9) 
Validity of the mass balance method to determine the amount of KTZ amorphous 
precipitate formed was verified by ultracentrifugation.22 KTZ supersaturated solutions of 
concentration ranging from 350 to 620 µg/mL were generated in ultracentrifugation tubes 
by the pH-shift method and immediately subjected to ultracentrifugation. KTZ precipitate 
pellet collected at the bottom of the tube was amorphous as confirmed by the observation 




w/w of absorbed moisture, determined by Karl Fischer titration, was lower than anhydrous 
amorphous KTZ Tg of 44℃ 138). The supernatant was discarded, and the precipitate was 
dried for 2 days at 30 mmHg in a vacuum oven at room temperature. The mass of the dried 
precipitate was determined using a microbalance.  
The calibration curve was utilized to determine the mass of amorphous precipitate 
present in dissolution media from its fluorescence intensity at 353 nm before it was 
ultracentrifuged. If an emission maximum at 353 nm was absent, the amount of amorphous 
precipitate in the dissolution media was considered nil. Crystalline precipitate was 
determined by mass balance as, 
 
Crystalline precipitate (fraction of dose) =
Total precipiate (fraction of dose) −





All experiments were performed in duplicate. 
4.3.8 Effect of absorption and polymer concentration on KTZ amorphous precipitate 
nanodroplets 
NTA was used to track the number density and diameter of KTZ amorphous precipitate 
nanodroplets as a function of time and in the presence of varying concentrations of pre-
dissolved HPMCAS polymer. The pH shift method was used to generate 300 µg/mL of 
KTZ supersaturated solution in FaSSIF-V2 media containing 0, 0.5, 1 and 1.5 mg/mL pre-
dissolved HPMCAS solution in non-sink ‘control’ and tuned AGS donor. Each run was 




media was introduced into the optical window of the NTA microscope where size and 
number density measurements of amorphous nanodroplets were made. Here, pH-shift 
method of supersaturation generation was utilized instead of ASD dissolution due to non-
discrimination between small ASD particles from amorphous precipitate nanodroplets 
under the microscope even after the dissolution media was filtered through a 1 µm glass 
filter.  
4.4 Results 
4.4.1 Crystalline and Amorphous Solubility Determination 
The crystalline and amorphous solubilities (determined by UV extinction method, 
Appendix, Figure A1) of KTZ at 37℃ without and with increasing dissolved 
concentrations of HPMCAS polymer are tabulated in Table 4.2.  
Table 4.2. Crystalline and amorphous solubility of KTZ in FaSSIF-V2 media containing 












A significant increase in the concentration of KTZ solubilized by bile micelles in 
FaSSIF-V2 media relative to phosphate buffer alone is observed (Chapter 3). Moreover, 
increasing HPMCAS concentration leads to both crystalline and amorphous solubility 
enhancement of KTZ. Amorphous solubility represents the concentration that marks the 
formation of drug-rich colloidal nanodroplets dispersed in the bulk aqueous phase that can 
scatter light and increase the UV extinction measured at a non-absorbing wavelength. With 
increasing concentration of pre-dissolved HPMCAS, a greater concentration of KTZ had 
to be added to FaSSIF-V2 before an abrupt increase in extinction was observed (Appendix, 
Figure A1). Moreover, increasing concentration of the polymer led to a decline in the 
extent to which the extinction increased after LLPS onset. This is in line with the NTA 
observations (Figure 4.2) wherein the number density of smaller amorphous nanodroplets 
increased with simultaneous increase in negative zeta potential as polymer concentration 
increased, indicating greater surface stabilization of the nanodroplets against coalescence 
with increasing HPMCAS concentration.  
HPMCAS is an amphiphilic polymer with the carbonyl functional group of the polymer 
interacting with the drug’s imidazole group in aqueous phase via dipole-induced dipole 
and hydrogen bonding interactions whereas the hydrophobic acetyl group is distributed 
into the drug-rich amorphous phase.139–141 However, it was previously shown that pre-
dissolved HPMCAS polymer decreased the amorphous solubility of KTZ even though it 
increased its crystalline solubility.139 Increase in crystalline solubility is indicative of 
significant interactions between the drug and polymer in the aqueous phase. The 
discrepancy in amorphous solubility trends between the previous and current study may 




as pH is known to greatly influence the ionization characteristics of both the drug and 
polymer and subsequently their interactions.141–143 The current study was conducted at pH 
6.5 while the earlier study was conducted at pH 8.0. Decline in amorphous solubility with 
increasing additive concentration suggests substantial distribution of the additive into the 
drug-rich phase at LLPS onset resulting in lower drug concentration dissolved in the bulk 
water phase.144 In this study, however, an increase in drug amorphous solubility with 
increasing HPMCAS concentration indicates an increasing proportion of the polymer in 
bulk aqueous phase undergoing hydrophilic interactions with the drug at pH 6.5 where 
more KTZ imidazole groups (pKa 6.5145) are ionized compared to pH 8.0. A higher degree 
of drug-polymer interactions in the aqueous phase may reduce the partitioning of the 
polymer into the drug-rich amorphous phase at pH 6.5 relative to pH 8.0. This solubilizing 
effect of the polymer additive is indicative of a reduction in the thermodynamic activity of 

































Figure 4.2. NTA micrographs of 290 µg/mL KTZ in FaSSIF-V2 media containing (a) 0, 
(b) 0.5, (c) 1, and (d) 1.5 mg/mL dissolved HPMCAS. (e) Change in number density, 









































4.4.2 Preparation of ASDs by Rotary Evaporation 
ASD fine powder samples were prepared with a single glass transition temperature (Tg) 
occurring between that of pure KTZ (44℃ 138) and pure HPMCAS (139℃) (Appendix, 
Figure A2). The Tg of the ASDs increased with increasing polymer loading indicating 
better stabilization by the polymer. 
4.4.3 Simultaneous Dissolution and Absorption Testing Study with AGS 
Eq. (4.1) was used to map 𝑘a,AGS as a function of hollow fiber surface area for absorption 
(𝑁 × 𝐴𝐼𝐿) and receiver fluid flow rate 𝑄 (Appendix, Figure A3a).  The value of 𝑘a,AGS of 
KTZ increases with 𝑁 × 𝐴IL and 𝑄.  At high values of 𝑄, however, absorption becomes 
permeation limited (Chapter 2).  
The physiological absorption rate constant of KTZ is 𝑘a= 0.013 min
-1.134 Upon setting 
the intraluminal fluid flow rate at Q = 500 µL/min and the number of hollow fibers at 
N=12, this rate constant (𝑘a,AGS) is attained (red star in Appendix, Figure A3a). Figure 
A3b in the Appendix displays a run of the AGS with these parameters, starting with a 
saturated solution of KTZ in the donor. The parameter 𝑘a,AGS was estimated by fitting the 
experimental fraction absorbed-time profile to Eq. (4.2) (black line in Appendix, Figure 
S3b) and was found to be 0.0130 ± 0.0001 min-1 which is the same as the physiological 𝑘a 
for KTZ.134 
Figure 4.3 shows KTZ receiver and donor concentration-time profiles measured during 
the simultaneous ASD dissolution and absorption study as well as ‘control’ non-sink 
dissolution-time profiles, for dose concentrations added below (90, 120, 180 µg/mL), at 




KTZ in FaSSIF-V2 media. Drug concentrations measured by in-line UV spectroscopy in 
the AGS donor and non-sink ‘controls’ are not quantitative since it has been demonstrated 
earlier that precipitated nanoparticles can both absorb and scatter light.43 Hence, 










Figure 4.3. KTZ concentration-time profiles in non-sink ‘controls’ and AGS receiver and 
donor obtained upon dissolution of 1:9, 2:8 and 3:7 KTZ:HPMCAS ASDs at 90 to 400 
µg/mL dose concentrations. 
 
In all the cases, the receiver concentration initially increases before attaining a 
maximum concentration (Cmax). The thin cellulose hollow fiber membrane used in this 
study allows rapid attainment of steady state in the intraluminal fluid. Immediate 
generation of 120 µg/mL dose concentration in the donor containing 0.48 mg/mL 
HPMCAS dissolved in FaSSIF-V2 media by addition of appropriate volume of 




minutes to attain Cmax in the intraluminal fluid which is significantly lesser than a lag time 
of 15 minutes seen upon 2:8 KTZ:HPMCAS ASD dissolution in the donor to generate the 
same dose concentration (Figure 4.4a). Thus, the delay in attaining Cmax here represents 
ASD dissolution time lag in the donor rather than hollow fiber membrane diffusion time 
lag as seen with mPES hollow fiber membrane in an earlier study with KTZ (Chapter 3). 
Lag times to attain Cmax in the donor and receiver profiles of the AGS as well as in non-
sink dissolution ‘controls’ are similar for a particular ASD which also demonstrates that 
the delay can be attributed to ASD dissolution.  
After Cmax, drug concentration in non-sink dissolution ‘controls’ plateaus and then 
decreases due to precipitation, the rate of decline increasing with increasing dose 
concentration. For 1:9 and 2:8 KTZ:HPMCAS ASDs at sub-amorphous solubility dose 
concentrations, the plateau occurs at the dose concentration itself. For dose concentrations 
exceeding the amorphous solubility, plateau occurs at the amorphous solubility 
concentration which represents the miscibility limit of KTZ in FaSSIF-V2 in the presence 
of HPMCAS. Since, at higher dose concentrations, HPMCAS concentration released into 
the media increases, the amorphous solubility and subsequently, the plateau concentration 
also increases. Also, due to higher HPMCAS loading in 1:9 KTZ:HPMCAS ASD and its 
subsequent release into the media, the rate of decline in drug concentration due to 
crystallization is lower at all dose concentrations relative to 2:8 KTZ:HPMCAS ASD. 
Dissolution rate (slope of the initial linear portions of dissolution-time profiles) increases 
with increasing dose concentration but decreases as drug loading in the ASD increases due 
to increasing hydrophobicity (Figure 4.4b). This was also observed in an earlier study117 




the concentration of KTZ upon release plateaus at a concentration significantly lower than 
the dose concentration and amorphous solubility in all the cases before it starts declining 
due to precipitation.  
In the AGS donor, concentration increases initially as the ASD dissolves, attains Cmax 
and then decreases due to both absorption and precipitation. This is reflected in the receiver 
as well. In the AGS donor and receiver, Cmax increases with increasing dose concentration. 
However, compared to the non-sink ‘control’, a lower Cmax is attained at sub-amorphous 
solubility dose concentrations in the AGS donor due to simultaneous drug absorption 
(Figure 4.4c). Moreover, similar to the non-sink ‘control’, we observe a lower Cmax in the 
AGS donor as polymer loading in the ASD decreases. Due to slow dissolution and 
simultaneous absorption, Cmax in both the donor and receiver is significantly lower at all 
dose concentrations with 3:7 KTZ:HPMCAS ASD compared to the ASDs with higher 
HPMCAS loading. Cmax was also found to be significantly higher at higher dose 
concentrations of 1:9 KTZ:HPMCAS ASD compared to 2:8 KTZ:HPMCAS ASD due to 
amorphous solubility limitation on dissolution in case of the latter. However, unlike in the 
donor, similar Cmax was observed at all dose concentrations in the receiver with the two 
ASDs. This may be due to a relative reduction in free KTZ fraction available for absorption 
in the presence of higher concentration of dissolved polymer. This hypothesis is evaluated 




























Figure 4.4. (a) Comparison of receiver concentration-time profiles obtained when 120 
µg/mL dose concentration was generated in the AGS donor by pH-shift method and ASD 
dissolution. (b) Dissolution rates of 1:9, 2:8 and 3:7 KTZ:HPMCAS ASDs in non-sink 
‘control’ as a function of dose concentrations. (c) Cmax as a function of dose concentration 
obtained in non-sink ‘control’ as well as AGS donor and receiver upon dissolution of 1:9, 




















Figure 4.5. KTZ amount (left Y-axis) and fraction absorbed normalized by the fraction 
absorbed from FaSSIF-V2 without any polymer (right Y-axis) plotted as a function of 
increasing polymer concentration. Initial KTZ concentration in the donor was at crystalline 
solubility.  
 
To explain the discrepancy between the donor and receiver Cmax trends, we sought to 
decouple the effect of polymer-bound drug species on absorption from the other co-
occurring phenomenon of precipitation by using donor solutions containing KTZ at its 
initial crystalline solubility concentration. Solution-state activity of KTZ in the presence of 
increasing concentration of pre-dissolved HPMCAS polymer was evaluated indirectly by 
measuring the amount of drug depleted from the donor. From Table 4.2 it is clear that as 
HPMCAS concentration increases, the crystalline solubility of KTZ also increases. 
However, at the end of 60 minutes, the amount of KTZ absorbed, i.e. KTZ solution-state 







































































































































































increasing polymer concentration (left Y-axis of Figure 4.5). This is similar to what was 
observed in the AGS study with ASDs above, wherein a higher Cmax in the AGS donor 
upon dissolution of an ASD of higher polymer loading did not result in a proportionately 
higher Cmax in the receiver. The fraction of KTZ absorbed in the presence of polymer was 
normalized by that absorbed from FaSSIF-V2 media alone and was plotted as a function 
of polymer concentration (right Y-axis of Figure 4.5). The normalized fraction absorbed 
decreases with increasing polymer concentration indicating declining absorption efficacy, 
i.e. the addition of solubilizing agents to a formulation to increase apparent dissolved 
concentration of KTZ will not necessarily guarantee a proportional increase in its flux 
across a membrane. This has been demonstrated several times in ex vivo and in vivo 
membrane permeation/absorption assays of drugs in the presence of solubilizing agents. 
For instance, a decrease in permeability of another poorly soluble compound, piperine in 
the presence of HPMCAS polymer, was shown via rat intestinal perfusion assay inspite of 
an increase in the drug’s solubility and was attributed to a reduction in drug’s free fraction 
available for absorption.119 This reduction in free fraction of the drug and absorption rate 
across rat intestinal membrane was also observed with KTZ in the presence of solubilizing 
bile micelles.8  It has also been demonstrated earlier how an increase in free fraction of 
drug fenofibrate in solution with changing ASD compositions translates directly to a higher 
fraction of drug absorbed in vivo in beagle dogs.118 Negative Flory-Huggins interaction 
parameter, i.e. favorable interactions between KTZ and HPMCAS140 in this case possibly 






4.4.5 Effect of absorption on drug and polymer release kinetics 
Figure 4.6 shows the cumulative percentage of drug and polymer released into the 
dissolution media of non-sink ‘control’ and AGS Donor [Eqs. (4.3)-(4.6)]. As discussed 
earlier, it is clear that as the hydrophobic drug KTZ loading in ASD increases, the rate of 
dissolution decreases. By 15 minutes, the drug released in the AGS donor was about 7-
10% higher than that released in the non-sink ‘control’, which can be attributed to depletion 
of drug by absorption that draws more drug out from the ASD formulation. In the case of 
1:9 and 2:8 KTZ:HPMCAS ASDs, drug and polymer release in both the ‘control’ and AGS 
donor is congruent throughout and nearly complete in 30 minutes. In case of 3:7 
KTZ:HPMCAS ASD, drug and polymer release is congruent until 15 minutes in the 
‘control’ and 30 minutes in the AGS Donor. This switch from rapid, congruent to slower, 
incongruent release of drug and polymer at specific drug loading in ASD was also observed 
in an earlier study and attributed to competitive kinetics between phase separation in the 
ASD and release of drug and polymer.147 Although incongruent, the percent drug released 
in AGS donor is greater than that observed in the ‘control. It may be hypothesized that a 
higher percentage of drug release from the ASD due to a larger concentration gradient 
created by absorption results in a reduced concentration of drug remaining in the ASD 
which in turn reduces the driving force for phase separation in the ASD. Observation of 
incongruence in drug and polymer release at a later time point and higher percentage of 
drug released in the AGS donor are indicative of longer induction time for phase separation 


























































































































































































































































































































































































































Figure 4.7. (a) Appearance of turbidity in non-sink ‘control’ and AGS donor upon 
dissolution of 2:8 KTZ:HPMCAS ASD at 300 and 400 µg/mL dose concentrations. (b) 
Estimates of total, amorphous and crystalline precipitate fraction (of total dose) using 







Figure 4.7a shows the turbid appearance of dissolution media due to precipitation in non-
sink ‘control’ and AGS donor following 120 min of dissolution of 2:8 KTZ:HPMCAS 
ASD at 300 and 400 µg/mL dose concentrations. The AGS donor at each dose 
concentration appears significantly less turbid than its non-sink ‘control’ counterpart, 
indicating lower precipitation in the dissolution media in the presence of absorption. This 
precipitate formed may be crystalline and/or amorphous and were quantified separately 
using mass balance Eqs. (4.7)-(4.10) along with fluorescence spectroscopy. The 3:7 
KTZ:HPMCAS ASD is not considered since dissolution was demonstrated to be 
incomplete (Figure 4.6) and mass balance will not be applicable.  
KTZ is an auto-fluorescent molecule that undergoes hypsochromic shift in response to 
decreasing environmental polarity due to LLPS with the fluorescence intensity increasing 
as amorphous precipitate concentration in the dissolution media increases (Appendix, 
Figure A4). Figure A5 in the Appendix demonstrates a good correlation between KTZ 
emission intensity, and the amount of amorphous precipitate calculated using mass balance. 
Determination of actual mass of amorphous precipitate in supersaturated solutions 
validates the mass balance calculations (blue circles in Appendix, Figure A5). Linear 
regression of the calibration curve in Figure S5 was used to determine the amount of 
amorphous precipitate in dissolution media of non-sink ‘controls’ and AGS donor at the 
end of 120 minutes.  
Figure 4.7b shows total as well as amorphous and crystalline precipitate fractions of 
KTZ. It is observed that the precipitated fractions increased as dose concentration was 
increased with amorphous precipitate appearing only at 300 and 400 µg/mL dose 




2:8 KTZ:HPMCAS ASD due to higher amorphous solubility as more polymer is released 
into the media in the former case. Crystalline precipitation is higher with 2:8 
KTZ:HPMCAS ASD due to lower polymer concentration released into the media upon 
dissolution resulting in lesser stabilization of the metastable supersaturated solutions 
against crystallization. In AGS donor, at all dose concentrations and any drug loading, 
crystalline precipitate fraction is lower than the non-sink control due to lowering of 
concentration in the dissolution media as absorption proceeds and subsequent reduction in 
driving force for crystallization. The amorphous precipitate fraction is also lower in AGS 
donor due to precipitate redissolution as absorption proceeds as will be discussed in more 
detail in the next section. In case of 1:9 KTZ:HPMCAS ASD at 300 µg/mL dose 
concentration, due to continuous absorption, the Cmax attained in the AGS donor possibly 
never attains the amorphous solubility concentration (Figure 4.4c), unlike the non-sink 
‘control’ resulting in no amorphous precipitation.  
This experiment demonstrates how the effect of absorption on amorphous and 
crystalline precipitation may be separately determined. While formation of crystalline 
precipitate is undesirable due to the drug reverting to its low solubility form, amorphous 
precipitate can form a reservoir of drug to rapidly redissolve and replenish KTZ in solution 
lost to absorption and maintain a constant drug concentration at amorphous solubility.90 By 
this measure, formation of amorphous precipitate is not completely undesirable. Infact, it 
has been demonstrated that KTZ upon administration orally forms supersaturated solution 
and amorphous precipitate in duodenal luminal media in humans but that does not 




















Figure 4.8. Snapshots from NTA videos of KTZ solution at 0, 5, 10 and 15 minutes after 
generation of 300 µg/mL supersaturated solution showing amorphous nanodroplets in (a) 
non-sink ‘control’ and (b) AGS donor. (c) Change in amorphous nanodroplet concentration 
and diameter from 0 to 15 minutes in non-sink ‘control’ and AGS donor as a function of 
dissolved HPMCAS concentration. 
































KTZ supersaturated solution (300 µg/mL) was generated using the pH-shift method in 
FaSSIF-V2 media containing 0 to 1.5 mg/mL pre-dissolved HPMCAS polymer in ‘control’ 
and AGS donor. The supersaturated solution was analyzed by NTA for size and 
concentration of amorphous nanodroplets for 15 minutes before significant crystallization 
commenced. Figures 4.8a,b show representative snapshots taken from NTA videos of 
supersaturated solutions containing 1.5 mg/mL pre-dissolved HPMCAS in ‘control’ and 
AGS donor acquired at 0, 5, 10 and 15 minutes. We observe a consistently high density of 
nanodroplets in the non-sink ‘control’ over 15 minutes (Figure 4.8a) as opposed to 
declining density observed in AGS donor as absorption proceeds (Figure 4.8b). Figure 
4.8c quantitatively shows the change in concentration and diameter of these amorphous 
nanodroplets. In the ‘control’, both the diameter and concentration of amorphous 
nanodroplets remain constant for 15 minutes at all concentrations of pre-dissolved 
polymer. In the AGS donor, on the other hand, both the concentration and diameter of the 
nanodroplets decrease with time. Concentration decline may be attributed to redissolution 
of amorphous precipitate to replenish the drug in solution lost to absorption. The decline is 
fastest in the presence of 1.5 mg/mL pre-dissolved polymer presumably due to the smallest 
diameter and largest surface area of the droplets resulting in faster redissolution. The 
concentration depletion rate decreases as polymer concentration decreases and the resultant 
droplet diameter increases. Moreover, as absorption of KTZ proceeds and the proportion 
of polymer relative to drug increases, greater surface stabilization of KTZ nanodroplets by 








ASD dissolution is a very complex process marked by speciation and phase 
transformations, which may reduce the free drug concentration in the dissolution media 
that is available for absorption. While it is relatively straightforward to separate crystallized 
drug in the media from free drug by filtration and/or microcentrifugation, removal of 
colloidal submicron or nanometer-sized species by traditional dissolution sample 
preparation methodologies and separately measuring the free drug concentration in 
solution can be quite challenging.43 Instrument-intensive methodologies such as nuclear 
magnetic resonance spectroscopy have been used to assess the colloidal species formed 
and to mechanistically elucidate the complex dissolution profiles of ASDs.148  However, it 
is more practical to use simpler analytical techniques. Dialysis methods, for example, have 
been successfully applied to measure free concentration during ASD dissolution; these 
techniques, while effective, can be labor-intensive and time-consuming.149  
The hollow fiber-based absorption module with a large surface area and low MWCO 
can be tuned to allow absorption of free drug species at a physiological rate. Mass transport 
of only free drug helps determine the thermodynamic activity of the resulting drug solution 
and how the presence of dissolution media additives and formulation excipients affect that 
activity. This in conjunction with other analytical techniques introduced earlier such as 
colorimetry and UV spectroscopy to assess HPMCAS polymer and drug release kinetics 
and fluorescence spectroscopy to measure drug concentration in the amorphous precipitate 
help evaluate the effect of dissolution and precipitation processes on drug absorption and 




Typically, during non-sink dissolution testing, AUCs of dissolution-time profiles are 
used to assess the “quality” or “efficacy” of different ASD formulations.150  To rank order 
1:9, 2:8 and 3:7 KTZ:HPMCAS ASDs, likewise, AUCs of non-sink ‘control’ drug 
concentration-time profiles were determined and are plotted in Figure 4.9a as a function 
of dose concentration. Having assessed the role of various drug species, the following 
explanations can be given to mechanistically account for the trend in AUCs: 
1. At low dose concentrations, the performance of ASDs may be ranked as – 
1:9 ASD ≡ 2:8 ASD > 3:7 ASD 
At high dose concentrations, on the other hand, 
1:9 ASD > 2:8 ASD ≡ 3:7 ASD 
2. At low drug concentrations, 2:8 KTZ:HPMCAS ASD performs similarly to its 1:9 
counterpart with comparable dissolution rates (Figure 4.4b). At high dose 
concentrations, in the absence of absorption, crystallization (Figure 4.7b) limits the 
efficacy of 2:8 KTZ:HPMCAS ASD and is comparable to that of 3:7 
KTZ:HPMCAS ASD. Moreover, at high dose concentrations of 2:8 
KTZ:HPMCAS ASD, we observe solubility-limited dissolution that occurs at a 
dose concentration of only 400 µg/mL in case of 1:9 KTZ:HPMCAS ASD (Table 
4.2, Figure 4.3). 
3. 3:7 KTZ:HPMCAS ASD exhibits low dissolution rate at all dose concentrations 
(Figure 4.4b). While this results in the lowest efficacy at low dose concentrations 
(Figure 4.6), at higher dose concentration, slow dissolution can translate to slower 
supersaturation generation and crystallization rate88,151,152, such that its efficacy is 




4. At high dose concentrations, efficacy of 1:9 KTZ:HPMCAS ASD may be 
overestimated due to non-discrimination between free and bound drug species 
(Figure 4.4c); concentration of the latter may be expected to be very high due high 
polymer loading in this ASD (Figure 4.5). 
To compare the ASDs’ efficacy using the AGS, the cumulative amount of drug 
absorbed at the end of 120 minutes was calculated using Eq. (6) and plotted in Figure 4.9b 
as function of dose concentration. The following inferences can be drawn in this case: 
1. At low dose concentrations, the performance of ASDs may be ranked as – 
1:9 ASD ≡ 2:8 ASD ≡ 3:7 ASD 
At high dose concentrations, on the other hand, 
1:9 ASD ≡ 2:8 ASD > 3:7 ASD 
These trends in ASD performance based on the amount absorbed by the AGS are 
significantly different from the trends determined using the non-sink ‘control’. 
2. Even though slow dissolution rate limits the concentration of drug released from 
3:7 KTZ:HPMCAS ASD (Figure 4.6), drug absorption from the donor media 
ensures a constant concentration gradient for dissolution of more drug from the 
ASD. Ultimately, at the end of 120 min, the amount of drug absorbed in case of 3:7 
KTZ:HPMCAS ASD is equivalent to 1:9 and 2:8 KTZ:HPMCAS ASDs, except at 
high dose concentrations of the 3:7 KTZ:HPMCAS ASD where lower polymer 
concentration in the media results in extensive crystallization.  
3. Due to absorption, in the 2:8 KTZ:HPMCAS ASD case, crystallization is much 




KTZ absorbed is high, comparable to 1:9 KTZ:HPMCAS ASD and significantly 
higher than 3:7 KTZ:HPMCAS ASD at high dose concentrations.  
4. The low MWCO of hollow fiber membrane would exclude most bile acid micelles- 
and polymer-bound drug species. A higher proportion of polymer-bound drug 
species may be expected to be formed in the case of 1:9 KTZ:HPMCAS ASD 
relative to 2:8 and 3:7 KTZ:HPMCAS ASDs, which releases the highest 
concentration of polymer into the media (Figure 4.5) at all dose concentrations. 
Inspite of high apparent donor concentration (Table 4.2), amount of drug absorbed 
in case of 1:9 KTZ:HPMCAS is not proportionally high due to lower 
thermodynamic activity or free drug fraction of KTZ relative to 2:8 KTZ HPMCAS 
ASD (Figure 4.5). In fact, the cumulative amount absorbed with lower 
thermodynamic activity 1:9 KTZ:HPMCAS ASD is on par with the more rapidly 
crystallizing 2:8 KTZ:HPMCAS ASD, and both are comparable to the slower 








Figure 4.9. (a) AUC of non-sink ‘control’ dissolution-time profiles and (b) total amount 
of KTZ absorbed from AGS donor at the end of 120 minutes plotted as a function of dose 







This study provides a scheme to disentangle the various dynamic equilibria occurring 
upon ASD drug and polymer release into the dissolution media. The equilibria are 
maintained in their dynamic state due to continuous drug removal by absorption at a 
physiological rate using the tuned AGS. The simultaneous dissolution and absorption study 
was conducted in conjunction with simple analytical techniques to mechanistically 
elucidate the influence of absorption on various bound drug species and vice versa. For the 
specific ASDs considered in this study, it was demonstrated that 
1. how the efficacy of 3:7 KTZ:HPMCAS ASD is underestimated due to incomplete drug 
release in the non-sink dissolution ‘control’ but progresses towards completion at the 
end of 120 minutes in the AGS donor as drug absorption drives ASD dissolution, 
2. how the efficacy of 2:8 KTZ:HPMCAS ASD is underestimated in non-sink dissolution 
‘control’ due to extensive precipitation which is significantly reduced in the AGS donor 
due to absorption, and 
3. how the efficacy of 1:9 KTZ:HPMCAS ASD is overestimated due to inclusion of both 
free and bound drug species in estimation of drug in solution available for absorption 
in the non-sink ‘control’ whereas the bound drug species were mostly excluded from 















Chapter 5: A Scheme to Establish In Vitro/In Vivo Correlation with a Weakly Basic 
















































































































































An in vitro/in vivo correlation (IVIVC) represents a quantitative relationship between some 
easily measurable in vitro characteristics of a dosage form and its in vivo performance, 
which is considerably more time- and labor-expensive to obtain.153 There are four levels of 
IVIVC that may be established. Level A correlation is the point-to-point correlation 
between in vitro (e.g. dissolution-time) and in vivo (e.g. plasma concentration-time) 
profiles.82 Level B correlates an in vitro summary parameter (e.g. mean dissolution time) 
with an in vivo summary parameter (e.g. mean absorption time).82 Level C compares a 
single time point from in vitro dissolution and in vivo profiles (e.g. Cmax, AUC) whereas 
multiple Level C correlates several parameters at multiple time points.82 Unsurprisingly, 
about 87% of submissions to the U.S. Food and Drug Administration (FDA) have used 
level A correlation, as the other levels do not reveal much information about the overall 
plasma concentration-time profile.82 IVIVC activities in the pharmaceutical industry have 
generally been focused on applying for biowaivers to avoid in vivo bioavailability and 
bioequivalence studies whenever there are formulation, manufacturing site and process 
changes.154  
It has been more than two decades since the FDA first published a guidance for IVIVC 
development. However, the number of IVIVC containing submissions has not increased 
substantially since 2008 owing to the low success rate (42%) of IVIVC acceptance by the 
agency.82 One of the key challenges identified for developing IVIVC is the lack of a 
suitable in vitro dissolution testing method in predicting  in vivo exposure. US 




dissolution testing had been primarily developed for routine quality control and batch 
release with little consideration to biorelevance.82,155 
In the past decade, media simulating the gastric and intestinal luminal conditions of 
pH, bile concentration, buffer capacity and osmolarity have been developed.38,133 These 
biorelevant conditions implemented in USP dissolution testing apparati are often sufficient 
to predict the in vivo dissolution of Biopharmaceutics Classification System (BCS) – I drug 
molecules.156  However, an absorptive compartment is quite critical while evaluating 
supersaturating formulations of low solubility, BCS-II molecules, which by definition have 
high permeability. Non-sink dissolution testing of such formulations can overestimate drug 
precipitation and underpredict drug exposure, especially of weakly basic drugs that can 
completely solubilize in acidic gastric media but can generate metastable supersaturated 
solutions as they transit through the more neutral intestinal lumen.157 Rapid absorption 
from the intestinal lumen reduces the dissolved drug concentration and in turn reduces the 
driving force for precipitation, which is not possible in a closed, dissolution testing 
apparatus. For instance, Carlert et al. observed significant precipitation of a weakly basic 
drug during in vitro dissolution testing, but a dose proportional increase in plasma exposure 
of the drug did not suggest significant precipitation in vivo.84  In that study, the authors 
recommended developing in vitro methods where there is continuous removal of drug from 
the dissolution media for future studies with formulations of BCS-II drug molecules. 
Psachoulias et al. developed a three-compartment in vitro set-up consisting of a duodenal, 
gastric and reservoir compartment.98 Drug solution was emptied from the gastric 
compartment at a first order rate, as drug free media from the reservoir simultaneously 




The sum of incoming flow rates of gastric and reservoir media into the duodenal 
compartment was made equal to the outgoing flow rate of the duodenal media.  This in 
vitro system accurately predicted the intestinal concentration of dissolved and precipitated 
weakly basic model compounds due to the simulation of drug removal by dilution. 
However, the operating parameters of this system were selected arbitrarily and cannot be 
rationally determined based on the absorption rate constant of a drug.  
The artificial gut simulator (AGS) equipped with an absorption module, can be used to 
conduct biorelevant dissolution testing (Chapter 2). The absorption module consists of 
hollow fibers that provide a large surface area for absorption. During dissolution testing, 
the absorption module is suspended in the drug donor compartment wherein the 
concentration gradient across the hollow fiber membrane drives the drug molecules to 
diffuse into the intraluminal fluid. Drug-free receiver media is continuously pumped 
through the hollow fibers, thereby maintaining an absorptive sink. Using the theory 
developed earlier, the AGS operating can be tuned to absorb the drug at a biorelevant rate 
(Chapter 2). In the present study, a scheme introduced before with caffeine to establish 
Level A IVIVC with AGS (Chapter 2), is implemented using a BCS-II model compound, 
dipyridamole (DPD). DPD is a weakly basic drug with poor aqueous solubility but high 
intestinal permeability (log P 2.74, pKa 6.24).
77 Gastric emptying and oral absorption of 
30, 50 and 90 mg doses of DPD were simulated using the AGS, which was tuned to absorb 
the drug at a physiological rate.77,158 
For IVIVC establishment, a two-stage method is most commonly implemented.82 The 
method involves deconvolution of in vivo plasma concentration-time profiles to obtain in 




absorbed in vivo and that dissolved in vitro.82 However, when considering mean plasma 
concentrations of multiple subjects, considerable variation in drug disposition between 
individuals can lead to erroneous results of drug absorption.82 Alternatively, a one-stage 
compartment based approach has also been used, which directly relates the time profiles of 
in vitro dissolution and in vivo plasma concentration by using one or multi-compartment 
pharmacokinetic models.159 This approach overcomes the limitation of indirect 
deconvolution methods for modeling complex absorption phenomena like pre-systemic 
metabolism and non-linear absorption as well as incorporating disintegration and 
dissolution mechanisms and changing solubility profile of the drug as it encounters 
different pH and bile acid content along the GI tract, thereby providing IVIVC a more 
mechanistic relevance.82  
In the present study, the one-stage compartment-based approach was used to establish 
IVIVC with DPD. A compartmental model describing DPD disposition pharmacokinetics 
(PK) in vivo was developed by fitting the PK model to plasma concentration-time profile 
obtained upon intravenous (IV) bolus dose administration of 20 mg DPD.158 Next, the 
amount of drug absorbed by the AGS was directly input into the central compartment of 
the PK model. The performance of the proposed approach was evaluated by comparing the 
predicted plasma concentration-time profile using the AGS and PK model with the in vivo 
profile.158 Additionally, the dissolved concentration and fraction of DPD precipitate in 







5.3 Materials and Methods 
5.3.1 Materials 
DPD was purchased from Sigma-Aldrich Co., MO and was used as received. Fasted-
state simulated intestinal fluid was prepared by dissolving FaSSIF-V2 powder 
(Biorelevant.com, DE) in 0.032 M pH 6.5 sodium phosphate buffer prepared using 
monobasic sodium phosphate monohydrate, dibasic sodium phosphate heptahydrate and 
sodium chloride, all purchased from Sigma-Aldrich Co.132,160 FaSSIF-V2 media was used 
as the drug donor media in the AGS. Bile acid and lecithin-free 0.032 M pH 6.5 phosphate 
buffer was used as the receiver media. Hydrochloric acid (HCl, 36.5 – 38.0%) was 
purchased from Sigma-Aldrich Co., and was diluted appropriately with deionized water to 
prepare a pH 2.7 solution.  
The AGS was constructed and set-up as described earlier (Chapter 4). Briefly, to 
construct the absorption module, the ends of regenerated cellulose based hollow fibers 
(Molecular weight cut off=13kDa, d=200µm, L=4.8cm, Spectra/Por® In Vivo 
Microdialysis Hollow Fibers, Repligen Corporation, CA) were potted into the inlet and 
outlet tubes of receiver/intraluminal media emerging from a cuvette cap (Azzota Scientific, 
DE) using a silicone UV-cure glue (Henkel Corporation, OH).   The corresponding cuvette, 







5.3.2 Tuning the AGS to absorb DPD at a physiological rate 
The operating parameters of the AGS, namely, the number of hollow fibers (N) and 
intraluminal fluid flow rate (Q) were selected to absorb DPD at a physiological rate 
constant, 𝑘𝑎, determined from the permeability coefficient of DPD across human intestinal 
epithelial membrane, 𝑃ℎ𝑢𝑚𝑎𝑛, and geometric surface area of the intestine-to-luminal 
volume ratio (𝑆𝐴/𝑉𝑖𝑛 𝑣𝑖𝑣𝑜). 
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Sugano estimated 𝑆𝐴/𝑉𝑖𝑛 𝑣𝑖𝑣𝑜 to be 2.3 cm
-1 using an equation relating human jejunal 
permeation rate of drug molecules to their fraction absorbed.161  𝑃ℎ𝑢𝑚𝑎𝑛 was estimated 
from the permeability coefficient measurement of DPD made across  Caco-2 cell 
monolayer (𝑃𝐶𝑎𝑐𝑜−2 = 1.24 ×  10
−6 cm/s162) using a correlation established at pH 6.5 by 
Sun et al.163 
𝑙𝑜𝑔 𝑃ℎ𝑢𝑚𝑎𝑛 = [0.6532 × 𝑙𝑜𝑔 𝑃 𝐶𝑎𝑐𝑜−2] − 0.3036 (5.2) 
𝑃ℎ𝑢𝑚𝑎𝑛 for DPD was calculated to be 2.91 × 10
−4 cm/s, which is approximately the same 
as estimates obtained in earlier studies using other methods.164–166 Finally, 𝑘𝑎 of DPD was 
estimated to be 0.0402 min-1.  
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was matched to the target 𝑘𝑎 for DPD by selecting N and Q (Chapter 2). Donor volume, 





respectively. The permeability coefficient of DPD across the cellulose hollow fiber 
membrane was determined to be (1.20 ± 0.04) x 10-4 cm/s using a method described 
previously (Chapter 2). Then, a mass transport study from an initially saturated solution of 
DPD in FaSSIF-V2 donor media [𝐶EL(0)] was conducted at 37℃ into drug-free phosphate 
buffer that was pumped through the tuned absorption module. A validating estimate of 
𝑘a,AGS was obtained by fitting the extraluminal concentration [𝐶EL(𝑡)]-time (𝑡) profile to 
Eq. (5.4) and comparing it to the “target” value, 𝑘𝑎.  
𝐶EL(𝑡) = 𝐶EL(0)𝑒
−𝑘a,AGS𝑡 (5.4) 
The optimized AGS was then used to conduct mass transport studies from supersaturated 
solution of DPD.  
5.3.3 Prediction of in vivo DPD intestinal concentration-time profile 
The AGS was used to simulate a previously published case study of oral absorption of 
DPD in which drug supersaturation and precipitation in the intestinal contents were 
evaluated in 12 healthy adults.77 30 and 90 mg doses of DPD pre-dissolved in 240 mL of 
pH 2.7 HCl solution were administered to the stomachs of intubated volunteers after which 
samples of intestinal contents were aspirated at several time points between 5 and 70 
minutes. In each sample, the dissolved concentration of DPD and precipitated fraction was 
determined. The raw data presented as Box-Whisker plots showing the median values, the 
10th, 25th, 75th and 90th percentiles were extracted using a WebPlot Digitizer.167  
The average intestinal volume in vivo is about 100 mL in humans, which remains quite 
constant after administration of 240 mL of a liquid even as gastric volume decreases from 




constant of 2.8 hour-1.168 The in vivo dose-to-intestinal volume ratios (Din vivo:Vin vivo) for 30 
and 90 mg doses are 0.3 and 0.9 mg/mL, respectively.  
The volume of FaSSIF-V2 media in the AGS donor is 1.2 mL. To match in vitro dose-
to-AGS donor volume ratio (Din vitro:Vin vitro) to Din vivo:Vin vivo for 30 and 90 mg DPD doses, 
0.36 and 1.08 mg of DPD, respectively, were dissolved in 2.88 mL of pH 2.7 HCl solution 
(total volume of 240 mL of pH 2.7 DPD oral solution administered in the in vivo study was 
also scaled down by the same factor as Din vitro and Vin vitro for the AGS study). FaSSIF-V2 
powder was dissolved in the HCl solution at a concentration of 3 mM bile acids and 0.2 
mM lecithin to prevent dilution of bile acids and lecithin in the donor media as HCl solution 
was added to it.77 Fractions of the stock solution were spiked into the extraluminal media 
every 15 min for 75 minutes at an overall first-order rate to simulate in vivo gastric 
emptying (Table 5.1). After each addition, the same volume of donor media as the stock 
solution added was pipetted out to maintain a constant 1.2 mL volume of donor media 
(Table 5.1). Absorption module was reinserted into the UV spectrophotometer donor 
cuvette after each dose fraction addition and the mass transport study was conducted for 
120 minutes at 37℃ with the tuned AGS. After each addition of the acidic stock solution, 
pH of the donor media decreased (Table 5.1). The final pH of the donor media at the end 
of 120 min was found to be 5.9 which is similar to the pH measured in human duodenum 
after administration of 300 mL of a pH 2.5 solution.169 Crystalline solubility of the weak 
base DPD (measured in the supernatant obtained by equilibrating excess solid drug in 
FaSSIF-V2 media followed by centrifugation) increased as the pH declined (Table 5.1). 
Separate experiments were conducted for 0, 15, 30, 45, 60, 75 and 120 minutes. At the end 




26KMR microcentrifuge, Thermo Fischer Scientific Inc., MA) for 10 minutes to remove 
precipitate particles if any and the dissolved drug concentration, 𝐶𝐸𝐿(𝑡), in the supernatant 
was determined by UV spectroscopy at 287 nm. When the experiment was conducted for 
120 minutes, the intraluminal fluid exiting the hollow fiber module was directed into a 
flow-through cell in which DPD concentration measurement was made by UV 
spectroscopy at 287 nm every two minutes. All experiments were conducted in duplicate.  
Fraction of DPD precipitated (𝑓𝑝𝑝𝑡) was determined by mass balance [Eqs. (5.5)-(5.7)].  
𝑇(𝑡) = 𝐷𝑜𝑠𝑒𝑖𝑛 𝑣𝑖𝑡𝑟𝑜(𝑡) − 𝐴𝐷𝑖𝑟𝐸𝑙(𝑡) − 𝐴𝐼𝐿(𝑡) (5.5) 
Here 𝑇(𝑡) is the total amount of drug (dissolved+precipitated) present in the donor at 
the end of each time point 𝑡 = 0, 5, 15, 30, 45, 60, 75 and 120 min, 𝐷𝑜𝑠𝑒𝑖𝑛 𝑣𝑖𝑡𝑟𝑜(𝑡) is the 
cumulative amount of drug added to the donor till 𝑡, 𝐴𝐷𝑖𝑟𝐸𝑙(𝑡) is the cumulative amount of 
drug directly eliminated till 𝑡 as the donor media was pipetted out after each addition of 
DPD stock solution, and 𝐴𝐼𝐿(𝑡) is the cumulative amount of drug absorbed by the 
intraluminal fluid determined till 𝑡, determined using Eq. (5.6). 
𝐴𝐼𝐿(𝑡) =  AUC𝐼𝐿,0−𝑡 × 𝑄 (5.6) 
where AUC𝐼𝐿,0−𝑡 is the area under the receiver concentration-time profile.  
𝑓𝑝𝑝𝑡 =
𝑇(𝑡) − [𝐶𝐸𝐿(𝑡) × 𝑉𝑖𝑛 𝑣𝑖𝑡𝑟𝑜]
𝑇(𝑡)
(5.7) 
Dissolved concentration as well as precipitated fraction of DPD in the extraluminal fluid 




Additionally, a no-sink ‘control’ experiment (no flow in the absorption module) was 
conducted in the same manner as outlined above with 90 mg equivalent dose and the 
fraction precipitated was determined by Eq. (5.7). In this case, since there is no absorption, 
𝑇(𝑡) was determined by subtracting 𝐴𝐷𝑖𝑟𝐸𝑙(𝑡) from 𝐷𝑜𝑠𝑒𝑖𝑛 𝑣𝑖𝑡𝑟𝑜(𝑡). 
Table 5.1. Summary of in vitro dosing schedule for the three doses of DPD, 0.36, 0.60 and 
1.08 mg (which are dose equivalents of 30, 50 and 90 mg DPD doses, respectively, in 
clinical studies), for simultaneous precipitation and absorption testing using the AGS. After 
each addition of the acidic stock solution, solubility of DPD increased as pH of FaSSIF-
V2 media decreased. 
 
5.3.4 Prediction of in vivo DPD plasma concentration-time profile 
A semi-log plot of DPD plasma concentration-time profile following a 20 mg IV bolus 
dose reveals that DPD declines in a triexponential manner (pink filled circles in the inset 
of Figure 5.2a).158 Thus, a three-compartment PK model describing DPD disposition was 
implemented in the Simbiology® toolbox (Matlab R2018a, MathWorks, MA) as shown in 
Figure 5.2b. The estimates of volume of distribution (Vd), distribution rate constants (k12, 
k21, k13, k31) and elimination rate constant (k10) were obtained using the Fit program of 
Simbiology® to fit the PK model to in vivo plasma concentration-time profile using a non-




The fitting result is shown in Figure 5.2a (black line) and the parameter estimates are given 
in Table 5.2. PK parameter estimates for DPD were also obtained in an earlier study but 







Figure 5.2. (a) Human DPD plasma concentration-time profile and (inset) semi-log plot 
(pink circles) obtained after a 20 mg IV bolus dose.158 Black line represents fit of (b) a 3-
compartment PK model describing DPD disposition to the plasma concentration-time 
profile.  
 














Human plasma concentration-time profile following oral administration of 50 mg DPD 
tablet was take from the literature.158 The mean gastric pH after administration of 200 mL 
water was found to be 2.7 in humans.170 Assuming that the DPD tablet was also 
administered with a glass of water (200 – 300 mL), one can expect the gastric pH in this 
case also to slightly increase to 2.7 from its resting pH of 1.5.171 Since DPD is a weakly 
basic drug, it can be expected to fully dissolve in acidic gastric media.  
To simulate DPD gastric emptying and absorption using the AGS, similar to the last 
experiment, a scaled-down dose of 0.6 mg was dissolved in 2.88 mL of pH 2.7 HCl solution 
with 3 mM bile acids and 0.2 mM lecithin. Fractions of this acidic stock solution were then 
added to the extraluminal FaSSIF-V2 media at 0, 15, 30, 45, 60 and 75 min as per the dose 
schedule shown in Table 5.1. The run was conducted for 240 minutes. DPD concentration 
in the intraluminal fluid [𝐶𝐼𝐿(𝐿, 𝑡)] was measured by UV spectroscopy at 287 nm every 
two minutes.  
𝐶𝐼𝐿(𝐿, 𝑡) was used to generate an input function 𝐼(𝑡) that describes the in vivo amount 
of drug absorbed with time.  




𝐼(𝑡) was ultimately input into the plasma compartment of the PK model [Eq. (5.9), Figure 
5.2b] to predict the in vivo plasma concentration time profile of DPD and establish Level 





























(𝑘13) − 𝐶𝑡2(𝑘31) (5.11) 
 
5.4 Results 
5.4.1 Tuning the AGS to absorb DPD at a physiological rate 
The absorption rate constant, 𝑘a,AGS of DPD, mapped as function of N and Q in Figure 
5.3a using Eq. (5.3), increases with increasing surface area for absorption and better sink 
conditions. The physiological 𝑘a of DPD is obtained when Q and N are set to 225 µL/min 
and 25, respectively. DPD fraction remaining in the donor declined to 0.1 at the end of an 
hour of mass transport from an initially saturated drug solution (solid red circles in Figure 
5.3b). The parameter 𝑘a,AGS was estimated by fitting the experimental fraction absorbed-
time profile to Eq. (5.4) (black line in Figure 5.3b) and was found to be 0.0402 ± 0.0005 





























Figure 5.3. (a) Family of plots obtained for 𝑘a,AGS as a function of Q and N using Eq. (5.3). 
To obtain a physiological 𝑘a of 0.0402 min
-1 of DPD [Eqs. (5.1) and (5.2)], an absorption 
module consisting of 25 hollow fibers and intraluminal receiver fluid flow rate of 225 
µL/min was used. (b) Fraction of DPD remaining in the donor when DPD at initial 
saturation solubility concentration was absorbed by the optimized absorption module. The 
black line represents the fit of experimental data points to Eq. (5.4) to estimate 𝑘a,AGS value 









5.4.2 Prediction of in vivo DPD intestinal concentration-time profile 
In vivo dissolved DPD concentration profiles in the duodenum after administration of 
30 and 90 mg doses solubilized in pH 2.7 HCl solution to human volunteers are shown as 
box-whisker plots in Figure 5.4.77 To simulate drug absorption in vitro from a small 
volume AGS donor, the drug doses were appropriately scaled down (Table 5.1). The entire 
dose was not dumped at once into the donor. Instead, fractions of DPD in HCl solution 
were spiked into FaSSIF-V2 media every 15 minutes for 75 minutes to simulate an overall 
first-order gastric emptying process (Table 5.1). This was done to generate supersaturation 
at a physiological rate, since evidence from earlier studies has suggested that excessively 
high initial supersaturation or a very fast rate of supersaturation generation, which occurs 
when the whole dose is dumped at once into the donor media, leads to a surge in maximum 
supersaturation followed by a sharp decline due to rapid nucleation and crystallization.76,88 
The concentration of dissolved drug in the AGS donor and absorbed drug in the 
intraluminal fluid of the tuned absorption module was measured for 120 min by UV 
spectroscopy. AGS donor concentration-time profiles are overlaid on the in vivo profiles 
in Figure 5.4 (black circles are interpolated for clear visualization).77 At the initial few 
time points, concentration of drug measured in the AGS donor slightly underpredicted the 
in vivo concentration especially in the case 90 mg dose equivalent (Figure 5.4b). DPD has 
a relatively low solubility in FaSSIF-V2 media at pH > 6 which exists for 30 minutes. DPD 
is also a moderately fast crystallizer.172 Upon addition of concentrated acidic stock solution 
of DPD to pH 6.5 FaSSIF-V2 media, supersaturated solutions are generated characterized 
by turbidity and subsequent formation of dispersed particles due to crystallization. This 




such as free fatty acids and cholesterol can further solubilize DPD and possibly limit 
crystallization.98 In fact, the mean solubility of DPD in human intestinal aspirates was 
greater than 450 µg/mL which is much higher than the measurement obtained in FaSSIF-
V2 media.77 Unsurprisingly, the fraction precipitated in the AGS donor (open black circles 
in Figure 5.5), estimated using mass balance Eqs. (5.5)-(5.7) when simulating absorption 
of 90 mg equivalent DPD dose was much higher than that observed in the GI tract (open 
red squares in Figure 5.5).77 In case of 30 mg equivalent dose, DPD fraction precipitated 
in the donor (solid black circles in Figure 5.5) was only slightly higher than the in vivo 
fraction (solid red squares in Figure 5.5). At later time points, as absorption proceeds and 
the donor media becomes more acidic (Table 5.1), DPD precipitate redissolves. 
Overall, we observe that the in vitro profiles quite adequately captured the in vivo data. 
We note here that about 55% of the drug was eliminated directly upon aspiration of AGS 
donor media with a pipette after each dose fraction addition. DPD has a bioavailability of 
only 43% as a large fraction of the dose administered was eliminated unchanged through 
the feces.173 Thus, direct elimination of DPD from the donor media also simulates direct 
elimination from the intestine. Additionally, an experiment with the 90 mg equivalent dose 
was also conducted with a ‘control’ (no flow in the absorption module) to represent non-
sink testing conditions. In this case, the decline in dissolved drug concentration 
(interpolated green stars in Figure 5.4b) during the initial time points is due to 
crystallization. At later time points, drug concentration increases as a higher fraction of the 
dose is added to FaSSIF-V2 media. The fraction of DPD precipitated in the non-sink 
‘control’ estimated using Eq. (5.7) (interpolated green stars in Figure 5.5) is much higher 




bioavailability will be predicted by non-sink dissolution testing relative to the AGS, 
consistent with our earlier observations with another weakly basic BCS-II compound, 









Figure 5.4. In vivo duodenal77 (red box-whisker plot) and in vitro AGS donor (black 
circles) and non-sink control (green stars) concentration-time profiles obtained upon 











Figure 5.5. Fraction of DPD precipitated in the duodenum77 (red solid squares, 30 mg dose; 
red open squares, 90 mg dose), AGS donor (black solid circles, 30 mg dose equivalent; 
black open circles, 90 mg dose equivalent) and non-sink control (green stars, 90 mg dose 
equivalent). 
(a) (b) 





























In vitro 30 mg
In vivo 30 mg
In vitro 90 mg
In vivo 90 mg




5.4.3 Prediction of in vivo DPD plasma concentration-time profile 
The plasma concentration-time profile of DPD after oral administration of a 50 mg 
tablet was predicted by scaling up and inputting the drug concentration absorbed in the 
AGS intraluminal fluid (Figure 5.6a) per unit time [Eq. (5.8)] into the central compartment 
of the drug disposition model (Figure 5.2b). The sudden decline in drug concentration in 
the intraluminal fluid at each point of addition of a fraction of drug dose is due to the 
removal of the AGS absorption module from the donor media resulting in absence of drug 
absorption, and dilution of intraluminal drug concentration, for less than a minute. 
After oral administration, DPD tablet is known to show an absorption lag-time of 34 to 
75 min due to slow tablet disintegration.174 Since a pre-dissolved acidic solution of DPD 
was used here to make dose additions to the AGS donor, a 45 min time delay was 
introduced in the input to the PK model to account for disintegration. Figure 5.6b compares 
the plasma concentration-time profile predicted by the AGS (black circles) with observed 
the data (red circles).158 The predicted profile agrees quite well with the in vivo profile 
including the observation of biexponential decline following the absorptive phase (inset in 
Figure 5.6b). The first phase of decline seen in IV bolus dose disposition (Figure 5.2a) 










Figure 5.6. (a) Intraluminal DPD concentration-time profile as caffeine was absorbed from 
the donor medium. Peaks represent the points of addition of fractions of DPD dose to 
simulate gastric emptying at a first order rate constant, 2.8 hour-1 (Table 5.1). (b) Overlaid 
in vivo (red circles) and predicted (black circles) plasma concentration-time profiles using 
the three-compartment PK model (Figure 5.2b) with AGS in vitro absorption data [Eq. 
(5.8)] as input. 
 
5.5 Discussion 
Developing IVIVCs has been encouraged by regulatory agencies for more than two 
decades, not just for supporting biowaiver applications, but also to facilitate decision 
making during early phases of drug development such as formulation optimization and 
design space establishment for critical material attributes and process parameters.82 This 
would enhance product and process understanding and ensure predictable performance 
throughout the product’s lifecycle. However, establishing IVIVC is not straightforward, 
and one of the frequently cited causes of failure is the lack of physiologically relevant 
methods to conduct dissolution testing.82 The purpose of this study was to demonstrate how 
absorption data from the AGS, tuned to absorb drug at a physiological rate, can be scaled-
up and input into a compartment-based PK model to predict in vivo intestinal and plasma 




Utilization of AGS is especially relevant for formulations of weakly basic drugs that 
supersaturate and precipitate in the neutral environment of the intestinal lumen after being 
transferred as concentrated solutions from acidic stomach.77 Crystallization in the gut from 
the metastable supersaturated solution can significantly reduce the rate of oral absorption 
and drug bioavailability. This effect should be more pronounced at higher doses since rate 
of precipitation increases with increasing degree of supersaturation, indicated by a less-
than-proportional increase in Cmax and/or AUC of plasma concentration-time profile with 
increasing doses.98  However, dose proportional increases in Cmax and AUC have been 
observed with most of the weakly basic drugs tested including DPD even when 
precipitation was observed in the intestinal lumen.12,13,34 This indicates that precipitation 
in vivo does not significantly influence the bioavailability of weakly basic drugs, probably 
due to a limited degree of precipitation and/or precipitate redissolution as the drug is 
continuously removed from the luminal media by absorption. This is inconsistent with the 
in vivo predictions of bioavailability made using closed dissolution testing methods that 
predict limited systemic drug exposure due to significant precipitation in the dissolution 
media.30,35  
In the current study with the AGS tuned to absorb DPD at a physiological rate (Figure 
5.3), the time profiles of dissolved concentration and precipitated fraction of the drug in 
donor predict the in vivo duodenal profiles better than the non-sink ‘control’ (Figures 5.4 
and 5.5).77 At a higher dose equivalent of 90 mg, a higher fraction of precipitate was 
observed with the AGS donor relative to in vivo measurements due to solubility limitation 
of the drug in FaSSIF-V2 media (Table 1) which can be resolved by making the media 




concentration in the intraluminal fluid was scaled-up [Eq. (5.8)] and input into the 3-
compartment disposition model for DPD (Figure 5.2b) to predict plasma concentration-
time profile obtained after administration of 50 mg DPD tablet (Figure 5.6). The predicted 
profile was in good agreement with the in vivo profile, and Level A IVIVC was 
established.158  
In general, the AGS can be useful in evaluating the effects of various gut physiological 
and formulation variables on drug absorption and ultimately, plasma concentration. For 
instance, addition of certain crystallization inhibiting polymers to the formulation or an 
increase in bile micelles in the intestinal lumen upon food intake is known to negatively 
influence absorption rate of certain drugs due to reduction in free fraction of the drug 
available for absorption.36,37 This reduction in unbound drug species and absorption rate 
was also indicated in the AGS study conducted with ketoconazole in the presence of 
hypromellose acetate succinate polymer in Chapter 4. AGS can then be used to evaluate 
different formulations for supersaturation, precipitation and absorption of unbound drug 
species to determine the influence of different excipients on drug plasma concentration-
time profile. Similarly, effect of food on drug absorption can also be predicted by 
simulating appropriate conditions in the AGS donor.  
The paradigm implemented in the present work with the AGS can be used to guide 
future IVIVC studies. During the drug discovery/development phase, in vivo data to 
estimate ka of the drug is often unavailable. The scheme introduced here can be used to 
estimate human ka from the Caco-2 cell monolayer permeability coefficient which is 
relatively easy to obtain. The low volume donor solution used here can support early phase 




for evaluating conventional dosage forms like tablets and capsules, the donor volume can 
be scaled up to, say, 100 mL to match the intestinal volume with proportional scale-up of 
the hollow fiber surface area. Moreover, to simulate selective absorption of unionized drug 
species, similar to the phospholipid intestinal epithelium, future studies can entail coating 
of the hollow fiber membrane with phospholipids to assess weakly acidic drugs and salt 
formulations.  
5.6 Conclusion 
A compartment-based approach was integrated with in vitro AGS test to establish IVIVC 
of a weakly basic, BCS-II drug. DPD was added to the AGS donor at a first order rate 
constant of 2.8 hour-1 (gastric emptying rate constant) to simulate physiological rate of 
supersaturation generation. Simultaneously, DPD concentration in the donor depleted due 
to absorption at a rate constant of 0.0402 min-1 and precipitation. In case of 30 and 90 mg 
equivalent doses, time profiles of DPD concentration and fraction absorbed in the AGS 
donor matched adequately with the in vivo data. Non-sink control, on the other hand, 
overpredicted the fraction of drug precipitated. In case of 50 mg dose, drug concentration 
absorbed by the intraluminal fluid was input into the central compartment of a 3-
compartment disposition model for DPD to predict the plasma-concentration time profile. 
The in vitro predicted and in vivo profiles agreed well with each other, establishing Level 
A IVIVC. This study demonstrates the importance of having an absorptive sink tuned to 
remove drug from the donor at a physiological rate to accurately simulate drug 




























This dissertation introduced a novel, convenient, inexpensive and material-sparing 
technique of conducting simultaneous, biorelevant dissolution and absorption testing of 
formulations of poorly soluble drugs by using the hollow-fiber based artificial gut 
simulator (AGS). The inherent flexibility of the system in terms of modifying the various 
operating parameters such as the number and length of hollow fibers (i.e. hollow fiber 
surface area for absorption), volume of the donor and intraluminal fluid flow rate, makes 
it attractive to be used with various drugs with differing absorption rate constants. For 
instance, in this study, the AGS was used with caffeine (ka=0.029-0.039 min
-1), 
ketoconazole (ka=0.013 min
-1) and dipyridamole (ka=0.040 min
-1) by simply varying the 
operating parameters.  
Chapter 2 described the design and working principle of the AGS in detail. A theory of 
mass transport across the hollow fiber membrane was developed and validated using a high 
aqueous solubility drug, caffeine. This theory was utilized to successfully tune the 
operating parameters of the AGS to match the in vitro and in vivo absorption rate constants 
of the model drugs used in this study. This step is key for conducting simultaneous 
dissolution and absorption tests with supersaturating dosage forms of BCS-II compounds. 
 In Chapter 3 it was demonstrated that reduction in drug concentration due to absorption 
simulated at a physiological rate reduced the driving force for precipitation in the AGS 
donor. This was unlike the non-sink ‘control’ where significantly higher precipitation was 
observed in the absence of an absorptive sink. Moreover, it was also demonstrated that 




precipitation in the AGS donor, indicating that it is critical to mimic in vitro absorption not 
just at a physiologically relevant rate, but at a physiologically observed rate. 
In Chapter 4, simple analytical techniques used in conjunction with the AGS enabled 
decoupling of the impact of drug absorption on dissolution and crystallization as well as 
impact of bound drug species on absorption. Previously, such an analysis was done by 
dialysis methods which, while effective, can be labor-intensive and time-consuming .149 
The AGS testing method was carried out relatively simply and was used to elucidate the 
complex dissolution profiles of different ASDs. 
In Chapter 5, the AGS was used to simulate gastric emptying and absorption of weakly 
basic, BCS-II compound, dipyridamole. The output of AGS i.e. the concentration of drug 
absorbed was scaled up and input into a 3-compartment disposition model for dipyridamole 
to accurately predict its in vivo plasma concentration-time profile, thereby establishing 
IVIVC. 
Overall, this dissertation highlights the significance of drug removal at a physiological 
rate of absorption and exclusion of bound drug species from the absorption module in the 
AGS simultaneous dissolution and absorption testing system for BCS-II drug formulations 








6.2 Recommendations for Future Work 
The experiments with the AGS described thus far provide a general framework for 
conducting simultaneous dissolution and absorption testing with BCS-II drug ASD 
formulations. However, there is much that remains to be explored to establish biorelevance 
in terms of hydrodynamics of the dissolution vessel and permeation through a phospholipid 
membrane (similar to the intestinal epithelium). The following subsections provide 
examples of avenues that are ripe for exploration. 
6.2.1 Understanding the role of the unstirred water layer in BCS-II drug absorption 
For some lipophilic, low aqueous solubility compounds, diffusion across the unstirred 
water layer (UWL) present adjacent to the epithelial membrane of the intestinal tract can 
be slower than absorption through the epithelial membrane itself.177 In such cases UWL 
permeability can be increased by maximizing the total drug available for diffusion, which 
can be in the form of unbound drug as well as drug bound to micelles, colloids and 
complexes.141,178,179 For instance, by introducing bile micelles and HPMCAS colloids in 
the dissolution media, the flux of itraconazole across the UWL was enhanced.95,180 On the 
other hand, absorption of ketoconazole was limited by diffusion across only the lipid-filled 
artificial membrane and not UWL since addition of solubilizing micelles did not increase 
the flux.180 To determine the rate-limiting steps to drug absorption as a function of drug 
properties, dose, pH and formulation characteristics, the hollow fibers can either be 
impregnated with phospholipids115 or the aqueous intraluminal fluid can be replaced by 
more lipophilic 1-octanol181 or 1-nonanol182 to simulate drug partitioning across the 




the membrane coated with phospholipids, then the absorption of that drug is UWL 
permeability rate-limited.  
6.2.2 Understanding the hydrodynamics in the AGS donor cuvette  
The hydrodynamics in the dissolution vessel of the AGS is controlled by the stirring 
rate. In this study, the stirring rate was arbitrarily chosen to ensure homogeneous 
distribution on the dissolution media contents in the donor. However, similar to USP-I and 
II apparati, there may be inherent variability in the hydrodynamics each time a test is 
conducted along with hydrodynamic dead zones.37 Poor hydrodynamics can also increase 
the thickness of the UWL adjacent to the hollow fiber surface, which can further slow down 
the mass transfer of a lipophilic drug.183 In vivo UWL is thought to be 30-100 µm thick, 
consistent with very efficient mixing at the surface of the gastrointestinal tract.184 However, 
UWL thickness adjacent to a PAMPA membrane in a well-stirred system was reported to 
be between 500-1200 µm.185 It then becomes imperative to study the hydrodynamics in the 
AGS donor as a function of stirring speed and stirrer type to determine if it can be made to 
mimic the GI conditions. In an earlier study, laser doppler velocimetry and computational 
fluid dynamics were used to experimentally map and computationally predict the velocity 
distribution inside a standard USP-II apparatus.37 These techniques may also be employed 
to the study the hydrodynamics in the AGS donor. 
6.2.3. Conducting simultaneous dissolution and absorption testing with non-ASD 
supersaturating formulations 
In the current state, both ionized and unionized drug species can indiscriminately 




available for absorption.33 Thus, the test should be made more selective to absorb only the 
unionized drugs to discriminate various formulations of salts and weakly acidic drugs. 
Impregnating the hollow fibers with phospholipids or replacing the aqueous intraluminal 
media with a more lipophilic solvent will be useful in this regard. 
6.3.4. Incorporating the hollow-fiber based absorption module into an Artificial Stomach 
and Duodenum apparatus 
An artificial stomach and duodenum (ASD) apparatus consists of gastric and duodenal 
compartments.186 Media from the gastric compartment is emptied into the duodenal 
compartment at a first-order rate. The AGS absorption module can be incorporated into the 
duodenal compartment to use the ASD apparatus to simulate gastric emptying and 
absorption simultaneously. The volume of the gastric and duodenal compartments can be 
set at 240 and 100 mL, simulating in vivo volumes, so that disintegration and dissolution 
testing of whole oral dosage forms like capsules and tablets can be done at later stages of 
drug development. 
6.3.5. High throughput screening of formulations 
Due to simplicity of testing with the AGS and inclusion of absorption module in a small 
volume UV spectrophotometer cuvette for continuous, in-line concentration measurements 
in the donor and receiver, the AGS can be used to screen multiple formulations 
simultaneously in a high-throughput manner in a multi-cell UV spectrophotometer during 
















Figure A1. Extinction of KTZ solution at a non-absorbing wavelength of 340 nm plotted 
as a function of increasing drug concentration in FaSSIF-V2 media in the presence of 0 to 









Figure A2. DSC thermograms of crystalline KTZ and HPMCAS alone as well as 1:9, 2:8 
and 3:7 KTZ:HPMCAS ASDs. Their phase transition temperatures that is, melting point 




























Figure A3. (a) Family of plots obtained for 𝑘a,AGS as a function of Q and N using Eq. (4.1). 
To obtain a physiological 𝑘a of 0.013 min
-1 of KTZ38, an absorption module consisting of 
12 hollow fibers and intraluminal receiver fluid flow rate of 500 µL/min was used. (b) 
Fraction of KTZ remaining in the donor when KTZ at initial saturation solubility 
concentration was absorbed by the tuned absorption module. The black line represents the 



























Figure A4. (a) Fluorescence emission spectra of auto-fluorescent KTZ solutions in 
FaSSIF-V2 media at concentration ranging from 25 to 616 µg/mL. (b) Abrupt increase in 
KTZ fluorescence intensity and decrease in emission maxima around amorphous solubility 
concentration (235 µg/mL) of KTZ in FaSSIF-V2 as the medium becomes increasingly 
non-polar upon LLPS. (c) Fluorescence emission spectra of KTZ in relatively polar ethanol 
simulating KTZ environment before LLPS and, (d) non-polar benzene simulating KTZ 






















Figure A5. Calibration curve to determine mass of amorphous precipitate generated upon 
ASD dissolution obtained by plotting fluorescence intensity as a function of mass of KTZ 
amorphous precipitate determined by mass balance and independently by 
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